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ABSTRACT 
Numerous studies have demonstrated that many nutraceuticals have potential 
capacity to mitigate the symptoms of aging and age-related disorders. We found that 
Royal Jelly (RJ/eRJ) consumption could extend C. elegans lifespan and increase stress 
tolerance in an IIS/DAF-16 dependent manner. In consideration that the transactivity of 
DAF-16 is tightly controlled by its co-factors, our further results indicated that SIR-2.1, 
14-3-3, and HCF-1 could interact with each other to fine-tune the activity of DAF-16.
Additionally, these co-factors were also required in RJ/eRJ mediated stress tolerance. 
Given that aging is characterized with progressively declined physiological 
functions, it is intriguing to investigate whether RJ/eRJ supplementation could slow down 
the development of neurodegenerative diseases. Strikingly, our results showed that 
RJ/eRJ supplementation delayed the β-amyloid (Aβ)-toxicity induced body paralysis in C. 
elegans AD model. The genetic analysis indicated that the RJ/eRJ mediated Aβ toxicity 
alleviation required Insulin/IGF Signaling (IIS) pathway and DAF-16, rather than HSF-1 
and SKN-1. Further research found that RJ/eRJ relied on DAF-16 to significantly 
improve the protein solubility in aged worms, which implied that RJ/eRJ supplementation 
promoted proteostasis and reduced proteotoxicity in AD worms. Additionally, RJ/eRJ 
also increased the solubility of Aβ species. In considering that RJ/eRJ supplementation 
slowed down the Aβ-induced paralysis in C. elegans, it is possible that RJ/eRJ mediated 
protection against Aβ toxicity might be dependent on increasing the solubility of Aβ 
species.  
iii 
Overall, our findings revealed that the anti-aging function of RJ/eRJ 
supplementation and underscored the relationship between the improved proteostasis and 
the prevention of neurodegenerative disorders. 
iv 
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CHAPTER ONE : INTRODUCTION 
1.1 Aging is genetically controlled 
Aging, a process of becoming older, is a universal inevitable process associated 
with declining physiological functions. Based on our knowledge, aging is characterized 
by declining stress resistance, increased homeostatic imbalance, and elevated risk of 
disease[1-3]. To date, the increase of aging population has been a big challenge in the 
United States. Statistical data estimates that more than 20% of the population will be over 
65 years old by 2030, and the cost of medical treatment for age-related diseases will be 
tripled in 2050. This aging population growth could slow the nation’s economic growth 
in the near future[4, 5]. Therefore, it is urgent for scientists to develop new therapeutic 
treatments to delay aging and the onset of age-related disorders. 
1.1.1 Aging is regulated through genetic pathways 
Most biological processes, if not all, are controlled by genes, and aging follows 
the same rule. It is genetically controlled by an elaborate genetic network[6-8].  
Numerous publications showed that some conserved genetic pathways regulate longevity 
and prevent the age related disorders (Figure 1.1). Dietary interventions and genetic 
alterations could manipulate genes and pathways to play an important role in the aging 
process[9-11].  
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Figure 1.1 Conserved nutrient signaling pathways regulating longevity.  (Fontana et 
al., 2010) 
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1.1.1.1 Model Organisms are utilized to study the molecular mechanism of aging 
Model organisms that mimic human responses provide us with a good platform to 
investigate the detailed molecular mechanism of diseases[12, 13]. Moreover, these classic 
model organisms offer numerous opportunities to evaluate the efficiency of drugs and 
therapeutic treatments[14, 15].  The well-established models in the research of aging 
including the yeast Saccharomyces cerevisiae, nematode Caenorhabditis elegans, fruit 
fly Drosophila melanogaster, hydra, zebrafish, and many rodents, which were crucial in 
identifying the conserved pathways that regulate human aging[16-18]. In our research, 
roundworm Caenorhabditis elegans (C. elegans) was utilized as an animal model to 
investigate the molecular mechanism of aging and age-related disorders.  
C. elegans is a free-living transparent multicellular animal simple enough to study 
the details of genetic pathways. C. elegans is considered a powerful model for studying 
aging due to its numerous advantages in culturing and genetic analysis[19, 20]. For 
instance, C. elegans is easy to culture to a bulk population, and it takes three days for the 
development of one generation and three weeks for the total lifespan. Moreover, these 
transparent animals can be used in high throughput automated experiments, which makes 
them an ideal tool to study the genetic regulation of aging[21]. Comparison of C. elegans 
and human genomes confirmed that nearly 80% of human disease genes and pathways 
are present in C. elegans, which indicates that C. elegans is a good model to study human 
disease[22-24]. However, the simple structure of C. elegans places some limitations for 
modeling human aging. They are multicellular organisms lacking tissues and organs, and 
therefore unable to regenerate their tissues, which make them limited in serving as a 
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model to study the aging of highly proliferative tissues[25-27]. Overall, although C. 
elegans is a primitive and simple organism, it shares many fundamental molecular 
structures and biological characteristics with more advanced organisms[12, 28]. 
1.1.1.2 Insulin/IGF Signaling (IIS) pathway and DAF-16 
Insulin/IGF Signaling (IIS) pathway is the most powerful pathways for regulating 
longevity and is highly conserved from C. elegans to human beings[29, 30]. In response 
to insulin-like peptides (ILPs), the transmembrane receptor DAF-2 (Insulin/IGF-1) 
triggers the activation of many protein kinases, including AGE-1/PI3K and AKT/PKB, 
which leads to phosphorylation and subsequent cytoplasmic retention of the main 
downstream effector DAF-16/FOXO (Figure 1.2). However, in some special conditions, 
such as low nutrients or starving, this pathway is inactivated and thereby DAF-16 is 
unphophorylated. Without phosphorylation, DAF-16 translocates from cytosol to nucleus 
and, in turn, elevates expression level of its target genes[31, 32]. These DAF-16 
downstream genes have many essential biological functions, such as   promoting stress 
tolerance, altering metabolic and development responses, improving immunity, and 
extending lifespan[33-35].  
In addition to DAF-16, heat shock factor 1 (HSF-1) and SKN-1 are two other 
critical transcriptional factors of the IIS pathway[32]. Specifically, HSF-1 regulates a 
series of heat shock proteins (HSPs) under stress conditions[36, 37]. HSF-1 is 
phosphorylated and inactive under normal condition; upon thermal stress, HSF-1 is 
released and translocated to the nucleus. As a result, HSF-1 induces the expression of 
HSPs to protect the proteome from destruction. It has been proposed that HSF-1 plays a 
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key role in lifespan extension and prevention of proteopathy, diseases caused by aberrant 
protein structure[38, 39]. The third transcriptional factor is SKN-1, which is also located 
at the downstream of IIS pathway and parallel to DAF-16 and HSF-1. Noticeably, SKN-1 
plays a very important role in anti-oxidative stress and metal detoxification[40, 41]. 
Although DAF-16, HSF-1, and SKN-1 have different biological functions and are 
parallel to each other, they mutually interact and some of their target genes are 
overlapping [38, 42, 43]. 
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Figure 1.2 The Insulin/IGF Signaling Pathway and DAF-16/FOXO.  (Nemoto et al., 
2004) 
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1.1.1.3 Important co-factors of DAF-16 
Numerous studies have indicated that the precise control of DAF-16 
transcriptional activity is a key regulatory step for longevity determination[44].  DAF-16 
activity is regulated by post-translational modifications, nuclear/cytoplasmic 
translocation, and association with transcriptional co-regulators. Although necessary for 
its activation, translocation of DAF-16 into the nucleus is not sufficient to stimulate its 
transcriptional activity[45, 46]. Association with additional co-factors is also necessary 
for nuclear DAF-16 activation [44, 47]. It has been proposed that SIR-2.1, HCF-1 and 14-
3-3 are important co-factors (binding partners) of DAF-16[3, 48, 49]. 
SIR-2.1, the C. elegans homolog of the yeast NAD
+
-dependent protein 
deacetylase, plays an important role in stress response and calorie restriction mediated 
lifespan extension[50, 51]. As an important co-factor of DAF-16, SIR-2.1 is thought to 
activate DAF-16 in conferring longevity as well as stress resistance. It is reported that in 
mammals, SIRT1(homolog of C. elegans SIR-2.1) can bind to and deacetylate forkhead 
proteins, which in turn influences the transactivity of FOXOs and thereby increases the 
resistance of mammalian cells to oxidative-damage induced apoptosis[52-54]. Numerous 
studies also demonstrated that the overexpression of SIR2 homologs in worms, yeast and 
flies extends lifespan, emphasizing the evolutionarily conserved role of SIR2 in longevity 
determination[54, 55]. Noticeably, recent studies revealed that heat stress stimulates the 
physical association of SIR-2.1 with DAF-16 via the scaffolding protein 14-3-3, which 
promotes the transactivation of DAF-16[48]. This finding indicated that SIR-2,1 could 
interact with other proteins to activate DAF-16. 
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14-3-3 proteins, also co-factors for DAF-16, function as docking proteins to 
bridge DAF-16 with other important co-factors. 14-3-3 proteins are small acid proteins, 
which could bind to diverse groups of signaling molecules to participate in a wide variety 
of cellular processes, including cell cycle checkpoints, DNA repair, cell differentiation 
and cell apoptosis[56, 57]. By binding to proteins, 14-3-3 proteins can induce the 
conformational change of the substrate proteins, sequester the substrates in the cytoplasm, 
or act as a scaffold that bridges two interacting partners as with DAF-16 and its co-
factors[58, 59].  
In C. elegans, there are two 14-3-3 proteins: PAR-5/FTT-1 and FTT-2. PAR-5 is 
required for cellular asymmetry in the early C. elegans embryo[60, 61]. FTT-2 sequesters 
DAF-16 in the cytosol by forming a protein complex, which in turn inactivates DAF-
16[62]. Between these two 14-3-3 proteins, only FTT-2 could affect dauer formation, 
DAF-16 localization, and transcriptional activates; PAR-5 does not have this function[3, 
62].  
Counter to these DAF-16 activation co-factors, the DAF-16 co-repressors down-
regulate DAF-16’s transactivity. Host Cell Factor-1 (HCF-1) belongs to a family of 
highly conserved HCF proteins and acts as a nuclear co-repressor of DAF-16. The main 
role of HCF-1 is to help fine tune the regulation of a subset of DAF-16 downstream genes 
to modulate survival under specific conditions. By regulating the function of DAF-16, 
HCF-1 is essential for longevity maintenance in C. elegans[49]. 
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In mammal studies, HCF-1 was reported to play a key role in cell cycle 
progression at the G1/S transition, M phase, and cytokinesis. In its diverse biological 
roles, mammalian HCF-1 acts by binding to and regulating many different transcriptional 
and chromatin factors and assembling appropriate protein complexes for context-
dependent gene regulation. In C.elegans, HCF-1 mutant exhibits declined reproductive 
ability and low penetrance of embryonic lethality, both phenotypes consistent with a role 
of HCF-1 in cell proliferation[63, 64]. Similar to the results found in mammalian research, 
HCF-1 in C. elegans also functions in proper cell cycle maintenance and cell 
proliferation[65]. Interestingly, Li et al reported that HCF-1 is also a critical longevity 
determinant and transcriptional regulator of DAF-16, which is necessary for maintaining 
normal lifespan and stress response in C. elegans[49, 66]. In the absence of hcf-1, more 
DAF-16 was released and localized to the nucleus and significantly up-regulated the 
expression of DAF-16 target genes. This up-regulation of DAF-16 indicates that HCF-1 
modulates C.elegans lifespan and stress response by acting as a negative regulator of 
DAF-16.  Furthermore, Riziki et al. reported that HCF-1 could also interact with SKN-1 
in stress response. Although HCF-1 is not regulated by IIS pathway, it still functions as 
an important factor to modulate downstream components of IIS pathway[67].  
To date, a growing body of evidence indicates that DAF-16’s co-factors 
physically interact with each other to regulate DAF-16’s activity[48, 68, 69]. For instance, 
in mammalian cells, HCF-1 affects the expression of several SIRT1/FOXO 
transcriptional targets and physically associates with both FOXO3 and SIRT1[65]. This 
interaction also exists in C. elegans genetic regulation. In C. elegans, SIR-2.1 forms a 
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protein complex with DAF-16 and requires DAF-16 activity to modulate lifespan. The 
protein complex of DAF-16 and SIR-2.1 forms in the nucleus and requires 14-3-3 
proteins as bridging molecules. Moreover, 14-3-3 proteins also physically associate with 
HCF-1. Based on genetic analyses, it is known that SIR-2.1 functions upstream of HCF-1, 
and both HCF-1 and SIR-2.1 functions upstream of DAF-16. Taken together, given 
certain signals, the activity of DAF-16 is regulated via the interplays between SIR-2.1, 
HCF-1 and 14-3-3 proteins. 
1.1.1.4 Other longevity-related pathways 
In addition to IIS pathway, other pathways, such as JNK, P38 MAPK, and TOR 
pathways, are also reported as critical modulators in aging and age-related diseases. 
Numerous evidence showed that some crossover molecules among these pathways 
contribute to form a complex genetic network to regulate longevity as well as other 
important biological processes (Figure 1.1) [70-73]. 
C-Jun N-terminal kinase (JNK) pathway has been implicated in critical biological 
processes such as cell development, survival, apoptosis, and cancer. The JNK family, a 
subgroup of the mitogen-activated protein kinase superfamily, is part of a signal 
transduction cascade that is activated by cytokines and external stresses, such as 
oxidative stress and heat shock stress[73, 74]. To date, it has been proposed that JNK 
pathway functions at the center of a signal transduction network that coordinates the 
induction of protective genes in response to oxidative stress, which can reduce the toxic 
effects of reactive oxygen species (ROS)[75, 76]. Moreover, under the heat shock stress, 
JNK-1 (an important component of JNK pathway) directly interacts and phosphorylates 
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DAF-16 to promote DAF-16 translocation into nucleus, which in turn extends the 
lifespan of C. elegans[77, 78].  
P38 mitogen-activated protein kinase (P38 MAPK) pathway is composed of series 
mitogen-activated protein kinases, which are activated by variety of cellular stresses such 
as cytokines, ultraviolet irradiation, heat shock, and osmotic shock. It is also involved in 
cell differentiation, apoptosis and autophagy[79, 80]. It is well known that p38 MAPK 
signaling pathway works in cooperation with IIS pathway to regulate C.elegans’ immune 
system in response to bacterial infection[80]. Dinh et al. reported that cranberry could 
protect C. elegans against Vibrio cholerae infection by inducing IIS/HSF-1 and P38 
MAPK signaling pathways[81].  
TOR (target of rapamycin) pathway, which regulates autophagy of proteins and 
lipids in response to nutrition levels, is also involved in longevity regulation. Reduced 
TOR signaling causes reduction in caloric intake without accompanying malnutrition, 
which leading to further longevity benefits. It is reported that a TOR pathway inhibitor, 
rapamycin, has been shown to extend lifespan in murine model[82, 83]. This finding 
further confirmed the lifespan extension function of TOR pathway. In addition to 
longevity, TOR pathway also controls several cellular processes including translation 
initiation and elongation, autophagy, mitochondrial respiration, and induction of stress 
response pathways[84-86]. 
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1.1.2 Dietary intervention is a feasible method to modulate longevity 
1.1.2.1 Dietary intervention and nutrigenomics 
Although dietary intervention and genetic alteration are two essential methods for 
manipulating genes and pathways in the aging process, dietary intervention is more 
feasible and efficient to promote healthy aging[87-89].  
Nutraceutical supplementation is the most popular and well-studied dietary 
intervention approach. A nutraceutical is defined as a product derived from food sources 
possessing pharmaceutical functions in addition to their basic nutritional benefits[90, 91]. 
To date, a growing body of evidence demonstrates how nutraceutical supplementation 
plays a key role in lifespan extension and alleviation of the symptoms of aging and 
stress[92, 93].  
Nutrigenomics is provided as a research tool to investigate how nutrients affect 
metabolic pathways and homeostatic control and consequently how nutrients affect the 
aging process and disease[94]. Nutraceuticals, by regulating genetic pathways, mediate 
lifespan extension and stress resistance. For instance, Ginkgo Biloba extract (EGb761), a 
traditional Chinese medicine derived from the fruit of maidenhair tree, was reported to 
extend lifespan and increase tolerance of oxidative stress and thermal stress in worms and 
rat models. Noticeably, this anti-aging effect is dependent on Ginkgo medicated 
overexpression of HSP-16.2[95]. Resveratrol, a functional extraction from grape seeds, 
was discovered as a SIR-2.1/SIRT1 activator, which delays the progression of 
neurodegenerative diseases[96]. Cocoa and its derivatives, another functional food, could 
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improve endothelial function and protect against cardiovascular disease in mammalian 
studies[97]. Taken together, numerous studies indicated that nutraceutical 
supplementation functions as a genetic regulator to improve a healthy aging. Additionally, 
the nutrigenomic approach highlighted the relationship between dietary interventions and 
pro-longevity, revealed the molecular mechanism of age-related disorders, and served as 
an efficient tool to further investigate how to prevent the neurodegenerative disease. In a 
current study, a nutrigenomic approach is being utilized to investigate the molecular 
mechanism underlying Royal Jelly mediated anti-aging effects. 
1.1.2.2 Royal Jelly’s beneficial effects 
Royal Jelly (RJ), a bee product, is secreted from the hypopharyngeal gland and 
mandibular gland of the worker honeybee. RJ plays a key role in the development of the 
queen honeybee, and it is part of the diet of honeybee larvae[98].  
It is reported that Royal Jelly has numerous pharmacological characteristics, such 
as anti-bacterial, antioxidant, anti-fatigue, and wound-healing properties[99-101]. 
Moreover, several studies carried out using mammalian models revealed that Royal Jelly 
could maintain the balance of sugar and lipid metabolism and protect the liver from virus 
invasions[102].  A chemical composition analysis has shown that Royal Jelly consists 
mainly of proteins, sugars, lipids, vitamins, and free amino acids. Based on the previous 
studies, it has been proposed that the 10-HAD, royalisin and apisin are the major 
components contributing to the above pharmacological functions[103]. 
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In modern diets, the use of Royal Jelly has significantly increased because of the 
trend toward the use of healthy, organic, nutraceutical, functional foods, and dietary 
supplements.  Besides the merits of Royal Jelly’s beneficial functions mentioned above, 
one phenomenon suggests that Royal Jelly also has the beneficial functions for anti-aging. 
In the honeybee Apis mellifera, queens live and reproduce for 1-4 years, but hive workers, 
which are derived from the same diploid genome, live for only 3 to 6 weeks. Queens are 
fed throughout their lives with Royal Jelly, while worker bees are fed with Royal Jelly for 
only a short period of time during their larval stages[98, 104]. Based on this phenomenon, 
it is believed that Royal Jelly might provide anti-aging agents for queens.  
The recently studies demonstrated that Royal Jelly may contain the pro-longevity 
factors and its pro-longevity effects may depend on the insulin signaling pathway[105, 
106]. However, the detailed mechanisms underlying the pro-longevity effects of royal 
jelly are largely unknown. Our lab focuses on the aging intervention study, which 
attempts to unveil the mechanism of royal jelly mediated lifespan extension. Furthermore, 
we will also investigate the potential correlation of pro-longevity effects and the 
prevention of age-related disorders by supplying royal jelly.  
1.2 Pro-longevity is often associated with increased stress tolerances 
Numerous studies supported that extended longevity is often correlated with 
increased resistance against various stressors, such as oxidative stress, heat shock, UV 
irradiation, osmosis stress and pathogen stress[107, 108]. 
1.2.1 Oxidative Stress 
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Oxidative stress is engendered by an imbalance between the production of free 
radicals and the biological system’s capacity to detoxify their harmful effects via 
antioxidants. Free radicals are formed in mitochondria during cell metabolism under 
normal conditions. As a scavenger, antioxidants could attack and neutralize free radicals 
and, in turn, prevents the oxidative stress. However, under chronic stress conditions or in 
aged cells, the effectiveness of antioxidant defenses is declined and the harmful free 
radicals can accumulate. As a result, the production of peroxides and free radicals could 
cause damage to all components of a cell, including proteins, lipids and DNA. 
Additionally, considering some reactive oxidative species act as cellular messengers in 
redox signaling, the accumulation of free radicals can disrupt the normal function of 
several signaling pathways[109, 110].  
In humans, oxidative stress is thought to be involved in the development of 
several aging-disorders, such as cancer, Parkinson's disease, Alzheimer's disease, 
atherosclerosis, heart failure, and myocardial infarction. However, reactive oxygen 
species are not always harmful. In short-term oxidative stress, free radicals could be used 
by the immune system as a way to attack and kill pathogens and thereby protect organism 
from bacterial infections[111]. 
1.2.2 UV Irradiation 
Ultraviolet (UV) irradiation is known to damage DNA through the formation of 
cyclobutane pyrimidine dimers (CPDs) and 6-4-photoproducts (6-4 PPs). UV induced 
DNA damage triggers cell cycle arrest and apoptosis[112]. 
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In somatic cells and tissues, the metabolism derived genotoxic agents and 
environmental factors (UV light or sunlight and radiation) cause DNA damage, resulting 
in alterations of DNA chemical structure, including a break in a strand of DNA, a base 
missing from the backbone of DNA, and DNA cross-linkages. These accumulative 
damages can give rise to mutations and cell death. In response to these negative effects, a 
series of DNA repair systems are activated to protect genomic integrity[113]. Once cell 
detects the DNA damage, the specific repair molecules could bind at or near the site of 
damage to fix the DNA alterations.  
Nucleotide excision repair (NER), a general DNA repair system in response to 
UV-induced DNA damage, functions to preserve and faithfully transmit DNA to the next 
generation in many organisms across life domains[114]. Upon detecting an irregularity in 
DNA structure, NER pathway is activated to remove the abnormal DNA and synthesize 
new base pairs to seal the nick, which in turn to play a key role in maintaining genome 
integrity[114]. In humans, mutations in NER genes cause several UV sensitive hereditary 
disorders. For example, cockayne syndrome (CS) patients, who have defects in 
transcription coupled nucleotide excision repair (TC-NER), suffer neurodecelopmental 
problems and premature aging. Similar evidence also showed in mice model, xeroderma 
pigmentosum (XP), a disease caused by XPD mutation, showed many symptoms of 
premature aging and extreme cancer proneness[115, 116]. 
In addition to NER pathways, certain pathways and molecules also participate in 
DNA damage response and conserved in mammals and C. elegans to repair different 
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types of DNA damages, such as BER (base excision repair), NHEJ (nonhomolgous end-
joining), HR (homologous recombination), ICL (interstrand crosslink repair), and 
mismatch repair[113]. 
Aging is often associated with the dysfunction of the body over time, and this 
regressive physiological function is caused by declined cellular repair system and 
accumulative cellular damages. Many studies have shown that high levels of DNA 
oxidative damages were detected in aging cells and organisms, which might further 
induce the late-onset neurodegenerative diseases. Several studies showed that some 
nutraceuticals might protect organisms from DNA damages. For instance, Inoue and his 
colleagues reported that Royal Jelly could extend the C3H/HeJ mice lifespan by reducing 
the DNA oxidative damage[106]. This finding indicated that RJ might have the potential 
to maintain genomic integrity in aged animals.  
1.2.3 Heat Shock Stress 
Heat shock stress is produced when an organism is shifted to a higher temperature 
than the ideal body temperature for certain period of time. As a result, the sudden 
increased temperature could cause cellular damage to proteins’ structure and function to a 
certain degree. In response to this thermal stress, the heat shock factor (HSF-1) is 
activated to dramatically up-regulate the expression of heat shock proteins (HSPs) to 
recover the destructed proteins and thereby protect organisms from this disruption[117]. 
It is well known that heat shock proteins (HSPs) play a critical role in protein 
folding, aggregation, and degradation. In addition to heat shock, upregulation of HSPs 
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could also be triggered by a variety of environmental stress conditions, such as 
inflammation, toxins (heavy metal, UV light, toxic chemicals, et al.), starvation, wound 
healing, and tissue remodeling. In normal condition, HSPs function as molecular 
chaperones to guide newly synthesized proteins folding in functional configuration and 
deliver them to right place at the right time, which in turn control protein quality and 
maintain the function of proteome[118]. Moreover, some HSPs could attach to proteins to 
signal their degradation via proteasome, affect their activities, and alter their cellular 
location. Noticeably, ubiquitin plays a key role in assisting aberrant proteins degradation, 
which decreases the proteotoxicity in cells[119, 120].  
Given that heat shock stress and aging condition are always associated with the 
production of destructed proteins (unfolded and misfolded proteins), which are in an 
urgent need to be refolded or degraded by HSPs to recover proteins’ function and thereby 
maintain protein homeostasis[121]. The disruption of this process could cause age-related 
disorders and proteopathy. Numerous studies revealed that some nutraceuticals could 
protect organisms from thermal stress. For instance, cranberry could protect C. elegans 
from heat shock stress by elevating the expression of HSPs[122]. Additionally, further 
research demonstrated that cranberry also protected C. elegans from Aβ toxicity and 
thereby delayed the development of Alzheimer’s disease[123].  
1.2.4 Osmotic Stress 
Osmotic stress is caused by a sudden change in the solute concentration around a 
cell, causing a rapid change in the movement of water across its cell membrane. Under 
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conditions of high concentrations of salt, water is drawn out of the cells through osmosis. 
This also inhibits the transport of substrates and cofactors into the cell thus “shocking” 
the cell[124].  
All organisms have mechanisms to respond to osmotic shock, with sensors and 
signal transduction networks providing information to the cell about the osmolarity of its 
surroundings, which activates responses to deal with extreme conditions. OSR-1 
regulates survival under osmotic stress via UNC-43 and a conserved P38 MAP kinase 
signaling cascade and likely regulating osmotic avoidance and resistance to acute 
dehydration by distinct mechanisms. OSR-1 plays a central role in integrating stress 
detection and adaptation responses by invoking multiple signaling pathways to promote 
survival under hyperosmotic environments[125]. Current research also suggests that 
osmotic stress in cells and tissues may significantly contribute to inducing many human 
diseases[126].  
1.3 Age-related disorders 
1.3.1 Neurodegenerative diseases  
 Aging is one of the greatest risk factors to cause age-related disorders, and 
neurodegenerative disease is the most common one in the aging population[127]. 
Neurodegenerative disease represents a series of diseases relative to the progressive loss 
of neurons’ structure or function, including ASL (amyotrophic lateral sclerosis), 
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Parkinson’s disease, Alzheimer’s disease, and Huntington disease. These diseases are 
incurable, resulting in progressive neuron cells degeneration and death[128]. 
 Sarcopenia is the age-related loss of the muscle mass and strength, which cause 
functional limitations in daily living, frailty and disabilities, and finally a higher mortality 
rate in the elderly patients. Given that satellite cells are resident myogenic progenitors in 
the skeletal muscles and plays a central role in the growth and regeneration of skeletal 
muscles, the main pathogenesis of sarcopenia is contributed to the age-related functional 
disability in satellite cells[129]; Parkinson’s disease (PD) is caused by the deposition of 
Lewy bodies in the central nervous system, which further influences the motor system. 
PD patients are suffering from movement-related problems, such as shaking, rigidity, and 
difficulty with walking. Moreover, dementia commonly arises in the advanced stages of 
disease[130]; Alzheimer’s disease is the most common cause of dementia, which triggers 
the problems of communication, thinking, and memory. Numerous studies demonstrated 
that the etiology of AD is due to the deposition of senile plaques (tau proteins and 
amyloid beta proteins) in the neurons, which disrupt the neuron cells’ transduction 
signaling induce neuron cell death[131]. Although  the pathogenesis is different in these 
neurodegenerative diseases, based on the previous research, there are some sub-cellular 
level similarities shared among these diseases: the majority of neurodegenerative diseases 
are engendered by genetic mutations and protein misfolding problems[132]. Discovering 
of these molecular similarities of neurodegenerative diseases not only provided us more 
opportunities to better understand how these diseases are generated but also helped us to 
further investigate the efficient therapeutic treatments[133]. 
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 Given that AD is a major type of age-related disorder and the most common cause of 
dementia worldwide, our study focused on studying the molecular mechanism of AD. 
1.3.2 Alzheimer’s Disease 
1.3.2.1 The etiology of AD 
     AD is a major type of neurodegenerative disease and the number one cause of 
dementia in the aging population. Brain atrophy and neuronal lesions are two obvious 
phenotypes of Alzheimer’s disease, which cause problems with thinking, memory, and 
behavior. The worldwide statistic data demonstrated that the number of AD patients will 
approach 63 million by 2030 and 114 million by 2050[134]. Therefore, there is an urgent 
need for scientists to develop efficient therapeutic treatment of AD. 
       To date, although a wealth of data surrounding AD has been published, the molecular 
mechanism underlying this disease is still unclear. There are several accepted hypothesis 
trying to explain the cause of AD. First, amyloid hypothesis is the most accepted theory 
in aging research, which claimed that the deposits of extracellular amyloid beta (Aβ) are 
the principal cause of neuron lesions. Amyloid precursor protein (APP) is considered to 
be a major source of Aβ. In normal conditions, APP is split by α-secretase and formed 
soluble αAPPs rather than toxic Aβ. However, β-secretase and γ-secretase could split 
APP into three fragments and, in turn, certain peptide fragments could aggregate into 
insoluble plaques in brain and therefore cause AD (Figure 1.3) [135]. One may note that 
Aβ is considered as a hallmark of AD as well as an important target of anti-AD drugs.  
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         The second hypothesis is called tau theory. The tau proteins, a group of important 
structural proteins in neuron cells, function to stabilize microtubules to maintain cell’s 
cytoskeleton. It has been proposed that AD is initiated by tau protein abnormalities. 
Based on the previous research, tau proteins are highly overexpressed in AD patients. 
Specifically, the majority of these proteins are hyper-phosphorylated, which are prone to 
pairing with others to form neurofibrillary tangles (PHF) inside nerve cells and thus result 
in destroying and collapsing the neuron cells[136].  
        The third hypothesis, genetic heritability of AD, claimed that AD is an inherited 
disease and well explained the etiology of early onset familial AD. The best known 
genetic risk factor is the inheritance of the ε4 allele of the apolipoprotein E (APOE), and 
people carrying the APOEε4 allele have higher risk to get AD. In addition to APOE, the 
genetic mutations in TREM2, presenillins 1 and 2, and APP have been associated with 
higher risk of developing AD[137]. Taken together, although the molecular mechanism 
of AD is intricate and complex, scientists will develop efficient anti-AD treatment in the 
near future.  
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Figure 1.3 The formation of amyloid plaques and neurofibrillary tangles are 
thought to contribute to the degradation of the neurons.  (Modified from 
BrightFocus Foundation, 2000) 
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1.3.2.2 The treatment of AD 
       Although AD is an incurable disease, there are several medications to temporarily 
mitigate the worsening of symptoms and slow the development of AD. From 1996 to 
2004, the U.S Food and Drug Administration (FDA) has approved five medications to 
treat AD, including donepezil, galantamine, memantine, rivastigmine, and dopepezil[138]. 
Although these drugs could improve cognitive ability, it is still unknown whether these 
medications could extend the lifespan of AD patients because these drugs are short-term 
effect cholinesterase inhibitors[139]. 
         In addition to these five FDA approved medications, Aβ inhibitors are also 
considered as anti-AD treatments, such as Aβ vaccine, anti-inflammation drugs, and anti-
cholesteric drugs. Clinical studies showed that these treatments are beneficial to prevent 
AD and treat early stages of AD patients[140, 141]. 
            To date, a growing body of evidence suggestes that dietary intervention is a good 
choice to slow down the age-related disorders. Numerous studies showed that anti-aging 
nutraceuticals could slow down the development of AD[142]. Moreover, reduction of IIS 
pathway could alleviate Aβ toxicity in C. elegans and mammals (Figure 1.4)[143, 144]. 
For instance, coca could mitigate the Aβ toxicity by reducing its aggregation in AD 
model, which is dependent on IIS pathway and DAF-16[97, 145]; Dostal and his 
colleagues reported that coffee significantly reduced Aβ toxicity, and this anti-AD effect 
required SKN-1[146]; Resveratrol, a SIR-2.1 activator, could protect neuron cells from 
apoptosis and thereby delay the development of AD and Parkinson’s disease[147]. 
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Collectively, nutraceutical supplementation not only extends lifespan and increases stress 
resistance, but also has beneficial effects to slow down the development of age-related 
disorders. 
 
 
 
Figure 1.4 Reduction of IIS pathway prevents neurodegeneration in worms and 
human.  (Moll et al., Swiss Med Wkly. 2014;144:w13917)  
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1.3.3 Cellular Proteostasis 
A growing body of evidence indicated that healthy aging is always associated 
with well-maintained proteostasis[148]. The imbalance of protein homeostasis could 
accelerate aging and induce neurodegenerative diseases. Proteostasis includes protein 
synthesis, folding, aggregation and degradation, which is the process to control the 
quality of cellular proteins[149]. Proteins are synthesized from ribosomes and folded to 
form the functional conformation. The endogenous and exogenous stresses could damage 
the proteins, forming the unfolded proteins. The unfolded and misfolded proteins could 
be refolded by heat shock proteins or be targeted by ubiquitin proteasome and lysosomal 
pathways to destruction and degradation[150]. This mechanical system keeps the 
function proteostasis in the health cells to keep the integrity of proteome and promote the 
cellular renewal[151]. However, in the aging cells or chronic persisting stresses 
conditions, this system is overwhelmed, which could form the aggregations and increase 
the proteotoxicity, which could increase the risk of neurodegenerative diseases. 
Functional proteostasis could improve healthy aging and reduce the risk of age related 
disorders development (Figure 1.5). 
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Figure 1.5 Proteostasis is the Process to Control the Quality of Cellular 
Proteins.  (López-Otín et al., 2013) 
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CHAPTER TWO : MATERIAL AND METHODS 
2.1 Experimental Procedures- longevity and stress response research 
2.1.1 Strains and Growth Conditions 
All wildtype strain and mutant strains were maintained at 20°C on NGM 
(nematode growth medium) seeded with Escherichia coli OP50 feeding strain. A 100µl 
of OP50 was dropped on the center of 60 mm NGM plates, which were allowed to dry 
overnight before the assays were carried out. Strains used in this research were: N2 
(Bristol, wild type), daf-16 (mgDf50), sir-2.1 (ok434), daf-12 (e1370), age-1 (hx-546), ftt-
2(n4426), and hcf-1(ok559). All the strains were obtained from the Caenorhabditis 
Genetic Center (CGC), University of Minnesota, USA. 
2.1.2 Preparation of RJ and eRJ 
The powder of RJ and eRJ were provided by Yamada Apiculture Center, Inc., 
Okayama, Japan. To prepare RJ and eRJ supplemented food, appropriate amount of RJ or 
eRJ in powder form were dissolved in sterile distilled water and suspended into the liquid 
NGM one day before the assay. 
2.1.3 Lifespan Assay 
All lifespan assays were carried out at 25°C. Synchronized populations were 
obtained by allowing 10-20 hermaphrodites lay eggs for 4 hours at 25°C and then 
removing the parents. The eggs were allowed to hatch and develop. Approximately thirty 
L4/young adult worms per plate (NGM plate contains 50 µg/mL FUDR to prevent the 
growth of progeny) were used for each assay. All the assays were carried out in triplicates 
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and a minimum of three independent trials were performed for all conditions. The dead 
worms were counted starting the day after transfer and exploding, protruding, bagging, or 
contaminated worms were censored if applicable. We defined the day when we 
transferred the L4/young adult worms as day 0 of adult age. All statistical analyses were 
carried out using SPSS software (IBM SPSS Statistics). Kaplan-Meier lifespan analysis 
was carried out and p values were calculated using the log-rank test. p <0.05 was 
accepted as statistically significant. 
2.1.4 Growth Curve of E.coli OP50 
The overnight culture of E.coli OP50 was 1:100 diluted in LB (200mg/mL 
Streptomycin), shaking at 37°C. RJ (2mg/mL) and eRJ (1mg/mL) were added in the LB 
medium respectively, bacteria treated without RJ/eRJ served as controls. All the bacteria 
were cultured at 37°C shaker and measured the OD600 reading every hour to compare 
the difference between each treatment. 
2.1.5 Stress Assays 
For three stress assays, wildtype N2 worms were pre-treated with 2mg/mL RJ or 
1mg/mL eRJ respectively for two generations at 25°C on OP50 seeded NGM plates. 
Worms on regular NGM OP50 seeded plates without RJ and eRJ served as controls. Each 
assay was carried out in three independent trials, and the data were pooled and analyzed 
using Student’s t test. p<0.05 was accepted as statistically significant. 
For the oxidative stress assay, 5 mM paraquat (sigma-Aldrich, Corp., St Louis, 
MO) was used to induce the oxidative stress environment. The RJ/eRJ-pretreated 
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L4/young adult worms and their controls were transferred onto NGM plates containing 
5mM paraquat, and survival was assessed by daily counting until all worms died. 
To assay for the protective effect on UV irradiation, RJ/eRJ pretreated L4/young 
adult worms and controls were transferred to RJ/eRJ (2mg/mL RJ and 1 mg/mL eRJ) 
plates and regular NGM plates respectively, and were irradiated at 0.05 J/cm
2
 for 20 
seconds. The survival of the worms was monitored at 25°C.  
For the heat shock assay, RJ/eRJ pretreated L4/young adult stage worms and 
controls were transferred to RJ/eRJ supplemented (2mg/mL RJ and 1 mg/mL eRJ) plates 
and regular NGM plates respectively. The plates were incubated at 35°C for 3 hours and 
then transferred back to 25°C. The survival of worms was monitored daily. 
2.1.6 Brood Size and Body Bend Assays 
The brood size assay was carried out by counting the offspring of a single worm 
on an NGM plate supplemented with or without RJ/eRJ (2mg/mL RJ and 1 mg/mL eRJ). 
Each L4/young worm was allowed to lay eggs at 25°C for 24 hours and was then 
transferred to a fresh plate until it ceased to lay eggs. The offspring were counted after 
they reached L3 or L4 phase. This assay was carried out in three independent trials. The 
data were pooled and analyzed using Student’s t test. p < .05 was accepted as statistically 
significant. 
For the motility assay, worms were pre-treated with or without RJ/eRJ (2 and 
1mg/mL, respectively) for two generations on NGM plates at 25°C. Three or four RJ/eRJ 
pretreated and non-treated L4/young adult nematodes were placed onto individual NGM 
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plates without OP50. The number of body bends performed in 3 minutes was counted, 
and then the number of body bends per minute was calculated. This assay was carried out 
in three independent trials. The data were pooled and analyzed using Student’s t 
test. p < .05 was accepted as statistically significant. 
2.1.7 DAF-16 Translocation Assay 
daf-16 (mgDf47) I; xrIs87 worms carrying a DAF-16-GFP fusion construct (Lee 
et ql., 2001) were treated respectively with eRJ (1mg/mL) or RJ (2mg/mL) for two days 
and were then observed under a fluorescence microscope (Nikon AZ100) to monitor the 
nuclear translocation of DAF-16-GFP. 
2.1.8 Gene Expression Analysis by Quantitative RT-PCR 
The nematodes were grown on NGM plates supplemented with or without RJ/eRJ 
at 25°C, until they reached the young adult stage, then collected in M9 buffer. RNA was 
prepared using RNAzol® RT reagent (Molecular Research Center, Inc.) and stored at –
80°C. Complementary DNA was prepared by using Invitrogen Superscript first strand 
synthesis system for RT–PCR (Invitrogen). Quantitative PCR (qPCR) was performed 
using SsoFast EvaGreen Supermix and the CFX96 real-time PCR detection system 
according to the manufacturer suggested protocol (Bio-Rad). The qPCR conditions were: 
95°C for 3 minutes, followed by 40 cycles of 10 seconds at 95°C and 30 seconds at 
60°C. act-1 was used as an internal control to normalize the expression levels of target 
transcripts. Each qPCR experiment was repeated three times using independent RJ/eRJ 
treatments and RNA preparations. The data were pooled and analyzed using Student’s 
t test, and p < .05 was accepted as statistically significant.  
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The qPCR primers for sod-3 are: 5′-CCAACCAGCGCTG-AAATT CAATGG-3′ 
(forward primer (F)) and 5′-GGAACCGAA GTCGCGCTTAATAGT-3′ (reverse primer 
(R)). Primers for daf-16 are 5′-CCAGACGGAAGGCTTAAACT-3′ (F) and 5′-ATTCGC 
ATGAAACGAGAATG-3′ (R). Primers for sir-2.1 are 5′-AGAACGCGCATTTCGCC 
ATATTAAG-3′ (F) and 5′-ATACTGACACTCCAGCGCCAG-3′ (R). Primers for hcf-
1 are 5′-GCGTTTACTTGGCCGTTAAGAATC-3′ (F) and 5′-GCCGTTCCCAGGTTTG 
ATTG-3′ (R). Primers for C32H11.4 are 5′-TTACTTCCCATCGCCAAAGT-3′ (F) and 
5′-CAATTCCGGCGATGTATGAT-3′ (R). Primers for F21F3.3 are 5′-CCGATTCGTT 
CCTTTTGAAG-3′ (F) and 5′-ACAACCGAATGTTCCAATCC-3′ (R). Primers for mtl-
1 are 5′-ATGGCTTGCAAGTGTGACTG-3′ (F) and 5′-CACATTTGTCTCCGCACTT 
G-3′ (R). Primers for act-1 are 5′-CCAGGAATTGCTGATCGTATGCAGAA-3′ (F) and 
5′-TGGAGAGGGAAGCGAGGATAGA-3′ (R). 
2.2 Experimental Procedures- C. elegans Alzheimer’s Disease Model Research 
2.2.1 Strains and Growth Conditions 
All strains were maintained at 16 °C on nematode growth medium (NGM) seeded 
with Escherichia coli OP50 feeding strain. Strains used in this study were as follows: N2 
Bristol (wild type), CL2006 (AD worm), and daf-16 (mgDf50). All the strains were 
obtained from the Caenorhabditis Genetics Center (CGC), University of Minnesota. 
2.2.2 Preparation of RJ and eRJ 
The powder of RJ and eRJ were provided by Yamada Apiculture Center, Inc., 
Okayama, Japan. To prepare RJ and eRJ supplemented food, appropriate amount of RJ or 
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eRJ in powder form were dissolved in sterile distilled water and suspended into the liquid 
NGM (2mg/mL RJ and 1mg/mL eRJ) one day before the assay. 
2.2.3 RNA Interference 
RNA interference (RNAi) clones were grown overnight at 37 °C on Luria Broth 
plate in the presence of tetracycline (12.5 µg/ml) and carbenicillin (25 µg/ml). Bacterial 
colonies were inoculated and grown for 8–12 hours, then induced with 2mM isopropyl β-
D-1-thiogalactopyranoside (IPTG) for 4 hours at 37 °C. Ten-fold concentrated RNAi 
bacteria were seeded onto RNAi plates containing 25 µg/ml carbenicillin. The RNAi 
constructs targeting daf-2, age-1, daf-16, hsf-1, skn-1, jnk-1, sir-2.1, hcf-1 and ftt-2 were 
obtained from the C elegans ORFeome RNAi library v1.1. 
RNAi efficiencies were checked at the same time with RNAi paralysis assay. 
CL2006 worms were synchronized by allowing 10–15 hermaphrodites lay eggs 6 hours 
on RNAi bacteria seeded NGM plates at 16 °C. The eggs were allowed to hatch and 
develop. The L4 /young adult worms were transferred to RJ/eRJ (2mg/mL RJ and 
1mg/mL eRJ, respectively) NGM plates (containing 50 µg/mL FUDR to prevent the 
growth of progeny) to maintain for 6 days. CL2006 worms on regular NGM (FUDR) 
plates without RJ/eRJ served as controls. Worms at the 6-day old stage were collected 
with M9 buffer into a 50~100 µl pellet. RNA extraction and qPCR method are described 
in 2.1.8. 
The qRT-PCR primers for daf-16 are as follows: 5′-CCAGACGGAAGGCTTA 
AACT-3′ (F) and 5′-ATTCGCATGAAACGAGAATG-3′ (R). Primers for hsf-1 are as 
follows: 5’-TTGACGACGACAAGCTTCCAGT-3’(F) and 5’-AAAGCTTGCACCAG 
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AATCATCCC-3’(R). Primers for skn-1 are as follows: 5’-GTAGCCGACGACGAAG 
AAGA-3’(F) and 5’-GAATTGAGGTGTTGGACGAT-3’(R). Primers for sir-2.1 are as 
follows: 5′-AGAACGCGCATTTCGCCATATTAAG-3′ (F) and 5′-ATACTGACACTC 
CAGCGCCAG-3′ (R). Primers for hcf-1 are as follows: 5′-GCGTTTACTTGGCCGTTA 
AGAATC-3′ (F) and 5′-GCCGTTCCCAGGTTTGATTG-3′ (R). Primers for ftt-2 are as 
follows: 5’-TCGACAAGTTCCTCATTCCA-3’(F) and 5’-TAGCTTTGCTGCGACTTC 
TC-3’(R). Primers for daf-2 are as follows: 5’-CGGTGCGAAGAGAGGATATT-3’(F) 
and 5’-TACAGAGGTCGCCGTTACTG-3’(R). Primers for age-1 are as follows: 5’-
AGTGGATTCGGAAACAATGC-3’(F) and 5’-GGAATCGATCGACACTTTCA-3’ (R). 
Primers for jnk-1 are as follows: 5’-ACAGTGGAACAGGAGGAGG-3’(F) and 5’-
ATACGGAAGTGGAGGTGGAG-3’ (R). Primers for act-1 are 5′-CCAGGAATTGC 
TGATCGTATGCAGAA-3′ (F) and 5′-TGGAGAGGGAAGCGAGGATAGA-3′ (R) 
2.2.4 Lifespan Assays 
All lifespan assays were carried out at 20 °C. Synchronous populations were 
obtained by allowing 10–15 hermaphrodites lay eggs overnight at 16 °C, and the parents 
were removed the next day. The eggs were allowed to hatch, and 30 L4/young adult 
worms per plate (NGM plate containing 50µg/ml 5-fluorour-aci1-2′-deoxyribose to 
prevent the growth of progeny) were used for each assay. The dead worms were counted 
starting the next day, and exploding, protruding, bagging, or contaminated worms were 
censored if applicable. We defined the day when we transferred the L4/young adult 
worms as Day 0 of adult age. All the assays were carried out in triplicates, and a 
minimum of three independent trials were performed for all conditions. All statistical 
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analyses were carried out using SPSS software (IBM SPSS Statistics). Kaplan–Meier life 
span analysis was carried out, and p values were calculated using the log-rank 
test. p <0.05 was accepted as statistically significant. 
2.2.5 Worm Paralysis Assays 
The assays using strain CL2006 were carried out as described by Cohen and 
colleagues. Synchronous populations of CL2006 worms were prepared on NGM plates 
by allowing 10–15 hermaphrodites lay eggs overnight at 16 °C, and the parents were 
removed the next day. The eggs were allowed to hatch, and 20 L4/young adult worms per 
plate were used for each assay. All paralysis plots were done in triplicates, and a 
minimum of three independent trials were performed per condition. Nematodes were 
scored as paralyzed if they exhibited “halos” of cleared bacteria around their heads 
(indicative of insufficient body movement to access food) or failed to undergo full body 
wave propagation upon the nose prodding. Worms were checked every day until all 
worms were paralyzed. The data were pooled, and the percentage of paralyzed worms 
was calculated and analyzed using Student’s t-test. p < 0.05 was accepted as statistically 
significant. 
2.2.6 Western Blotting of Aβ Species 
Rabbit polyclonal Aβ1–42 primary antibodies were from abcam (ab39377). For 
Western blot analysis, CL2006 worms were synchronized by allowing 10–15 
hermaphrodites to lay eggs overnight on OP50 seeded NGM plates at 16 °C. The parents 
were removed, and eggs were allowed to hatch and develop to the L4 stage. Subsequently, 
worms were transferred to RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, respectively) 
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containing NGM plates and continued to grow at 20 °C. CL2006 worms on regular NGM 
plates without RJ/eRJ served as control. After 10 days of growth, worms were transferred 
to micro-centrifuge tubes and washed with S-basal followed by protein immobilization 
on polyvinylidenefluoride (Bio-Rad) membrane. Polyvinylidenefluoride membrane was 
incubated with primary antibodies (1:1,000) diluted in 5% nonfat dry milk and then with 
secondary, HRP-conjugated goat anti-rabbit antibodies (Genscript, A00098; diluted 
1:10,000). ACTIN was used as loading control, and the anti-ACTIN antibodies 
(MAB1501) were from EMD Millipore. Detection was undertaken with standard ECL 
protocol. Mean intensity of Aβ signals was analyzed using Image-J software (National 
Institute of Health). 
2.2.7 Soluble Protein Extraction 
The soluble protein extraction was performed as described previously with 
alterations. Synchronous populations of eggs were prepared by 20% alkaline hypochlorite 
treatment of gravid adults grown at 16 °C. Eggs were allowed to hatch and develop by 
transferring to OP50-seeded NGM plates containing RJ/eRJ (2mg/mL RJ and 1mg/mL 
eRJ, respectively) at 20 °C. Eggs hatched and developed on OP50-seeded NGM plates 
without RJ/eRJ served as controls. Both worms treated with or without RJ/eRJ 
supplementation were collected 10 days after L4 stage. Three separate replicates of each 
sample (about 200mg [wet weight] of worms) were collected. Total protein extracts were 
produced in phosphate-buffered saline by sonication on ice, and then the total protein 
concentration was determined by conducting a bicinchoninic acid assay. Next, the 
normalized protein samples were centrifuged for 10 minutes at 14,000g to remove the 
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insoluble fraction. The same volume of supernatants (soluble fraction) was loaded and 
analyzed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Mean intensities 
of protein bands were analyzed using Image-J software (National Institute of Health). 
2.2.8 Gene Expression Analysis by Quantitative Real-time PCR 
CL2006 worms were synchronized by allowing 10–15 hermaphrodites lay eggs 6 
hours on OP 50 seeded NGM plates at 16 °C. The eggs are allowed to hatch and develop.  
The L4 /young adult worms were transferred to RJ/eRJ (2 and 1mg/mL respectively) 
NGM plates (containing 50 µg/mL FUDR to prevent the growth of progeny) to maintain 
for 6 days. CL2006 worms on regular NGM (FUDR) plates without RJ/eRJ served as 
controls. Worms at the 6-day old stage were collected with M9 buffer into a 50~100 µl 
pellet. RNA extraction and RT-PCR method are described in 2.1.8.  
The qRT-PCR primers for daf-16 are as follows: 5′-CCAGACGGAAGGCT 
TAAACT-3′ (F) and 5′-ATTCGCATGAAACGAGAATG-3′ (R). Primers for hsp-
12.6 are as follows: 5′-ATGATGAGCGTTCCAGTGATGGCTGACG-3′ (F) and 5′-
TTAATGCATTTTTCTTGCTTCAATGTGAAGAATTCC-3′ (R). Primers for hsp-
16.2 are as follows: 5′-TTGCCATCAATCT CAACGTC-3′ (F) and 5′-CTTTCTTT 
GGCGCTTCAATC-3′ (R). Primers for hsp-70 are as follows: 5′-CGTTTCGAAGA 
ACTGT GTGCTGATCTATTCCGG-3′ (F) and 5′-TTAATCAACTTCCTCA ACA 
GTAGGTCCTTGTGG-3′ (R). Primers for act-1are as follows: 5′- CCAGGAATTG 
CTGATCGTATGCAGAA-3′ (F) and 5′-TGGAGAGGGAAGCGAGGATAGA-3′ (R).  
Primers for sod-3 are as follows: 5′-CCAACCAGCGCTG-AAATT CAATGG-3′ (F) and 
5′-GGAACCGAA GTCGCGCTTAATAGT-3′ (R). Primers for mtl-1 are as follows: 5′-
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ATGGCTTGCAAGTGTGACTG-3′ (F) and 5′-CACATTTGTCTCCGCACTTG-3′ (R). 
Primers for sip-1 are as follows: 5’- GGTCAATCTTGAGGGACACG-3’ (F) and 5’- 
GAGTGAACGATCTCTTGCTG-3’ (R). Primers for aip-1 are as follows: 5’- 
GAGCGGGATCACAGTTGTGAG-3’ (F) and 5’- GATGTGATTGAATCCGTCCAG-3’ 
(R). Primers for F10D7.5 are as follows: 5’- GCACTAGAGGACCATTACAGTT-3’ (F) 
and 5’- CGTTCTCGTCAATCTCGATAGG-3’ (R). Primers for ZK218.8 are as follows: 
5’- TGCTACTGGCTGTGTGTTAG-3’ (F) and 5’- CAATAGTTCCGGCATTCACATA 
AT-3’ (R). Primers for T05G5.10 are as follows: 5’- GGAGACTTGGGAAACACTATC 
C-3’ (F) and 5’- TGTATCCGAGAATAGCCTCCT-3’ (R).  Primers for Y71H2AR.2 are 
as follows: 5’- GAGTTGTGGCAGAGGGTAATG-3’ (F) and 5’- GGATGGGTTGTAG 
ATTCCGATTT-3’ (R). 
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CHAPTER THREE : THE MOLECULAR MECHANISM OF ROYAL JELLY 
MEDIATED LIFESPAN EXTENSION 
3.1. Introduction 
Aging is an inevitable process associated with physiological decline and higher 
risk to get disease. Nowadays because of the development of technology and medical 
treatment, the population structure changed and population aging already became a 
challenging issue to our society. Age-related diseases affect aging population and their 
families; moreover, the increasing medical cost brings concerning economic burden to 
the society and government. In order to solve this problem, more and more scientists are 
dedicated to doing research in the anti-aging field, not only study the molecular 
mechanism of aging, but also look for effective methods to delay the onset of age-related 
disorders. Although the anti-aging research field is very new, it is extremely urgent for 
scientists to find out efficient solutions to slow down the age-related diseases 
development, therefore, improving the aging populations’ quality of life. 
As same as other biological processes, aging is also controlled by genes[31]. 
Insulin like signaling (IIS) pathway is considered as a master regulator to modulate 
longevity and metabolism. DAF-16 is a downstream component of IIS pathway, which 
functions as an essential transcriptional factor to regulate cell proliferation, metabolism, 
and longevity[38]. Similar to other transcriptional factors, DAF-16 is tightly controlled 
by other co-factors.  SIR-2.1, HCF-1 and 14-3-3 are reported as major DAF-16 co-factors 
and physically interact with DAF-16 to regulate its activity[62].  
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It is well known that dietary intervention and genetic alteration could manipulate 
genes and pathways to regulate longevity in the anti-aging research field[152]. 
Comparing to other methods, dietary intervention is the most efficient and safe manner to 
delay the development of age related disorders[88]. Royal Jelly is a popular functional 
food in Asian market, which has a series of beneficial effects of health. As a bee product, 
Royal Jelly is secreted from the pharyngeal glands of nurse worker bees (Apis mellifera) 
to feed larvae. Adult queens are fed only with Royal Jelly for the whole life and it enables 
her to outlive worker bees nearly thirty fold. Most people believe that Royal Jelly might 
have the pro-longevity factors, and the Japanese scientists confirmed this hypothesis[105]. 
They reported that Royal Jelly has the anti-aging beneficial effects, but the mechanism is 
still unclear. In my research, I will focus on investigating the molecular mechanism of 
Royal Jelly’s anti-aging functions. 
Our Royal Jelly powders were provided by Yamada Japanese Company, and there 
were two types of Royal Jelly powders used in our research; one was enzyme treated 
Royal Jelly (eRJ), and the other was regular Royal Jelly (RJ). Caenorhabditis elegans (C. 
elegans) was used as a model animal to investigate RJ/eRJ’s anti-aging function. Our 
data showed that RJ/eRJ supplementation extended C. elegans lifespan in a dose 
dependent manner. IIS/DAF-16 and DAF-16’s co-factors were required in this RJ/eRJ 
mediated lifespan extension. Our proposed model was: under the supplementation of 
RJ/eRJ, SIR-2.1, HCF-1 and 14-3-3 could interplay with DAF-16 to fine-tune its 
transactivity to extend C. elegans lifespan. 
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3.2. Experiment Results 
3.2.1 Supplementation of RJ/eRJ extends C. elegans lifespan in a dose-dependent 
manner 
In order to determine whether RJ/eRJ has the pro-longevity beneficial effects, we 
treated the wild type C. elegans (N2 worms) with different concentrations of Royal Jelly, 
ranging from 0mg/mL to 5mg/mL, and carried out the lifespan assays to observe worms’ 
survival at 25°C. Our results showed that N2 worms treated without RJ/eRJ (control 
group) showed a regular lifespan. The mean lifespan was 12.79 days. Afterwards we 
compared the mean lifespan of RJ/eRJ supplemented worms to control worms to 
investigate whether RJ/eRJ could extend the lifespan of C. elegans. 
In RJ treatment, the mean lifespan of 0.4mg/mL RJ treatment was 0.23 day longer 
than non-supplemented controls, but this lifespan extension was not significant. For the 
higher concentration RJ treatment, 1mg/mL to 3mg/mL RJ significantly increased C. 
elegans mean lifespan from 12.79 days to 13.52days, 15.52 days, and 14.39 days, 
respectively. However, the highest concentration 5mg/mL RJ hardly influenced C. 
elegans mean lifespan (Figure 3.1 A and Table 1). Based on this result, we found out the 
best concentration of RJ for lifespan extension was 2mg/mL, which increased 21.34% of 
lifespan comparing to control group.  
In eRJ treatment, low concentration of eRJ (0.4mg/mL) showed a similar lifespan 
as the control group, which indicated that this low concentration of eRJ cannot extend N2 
worms’ lifespan. For the higher concentration of eRJ treatment, 1mg/mL to 3mg/mL eRJ 
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could extend worms’ lifespan significantly, from 12.79 days to 14.44 days, 14.09 days, 
and 13.95 days, respectively. However, the highest concentration 5mg/mL eRJ barely 
affected C. elegans mean lifespan (Figure 3.1 B and Table 1). Based on this result, we 
found out that the best concentration of eRJ treatment was 1mg/mL, which increased 
11.33% of lifespan comparing to control group.  
Taken together, the lifespan results showed that both RJ and eRJ could extend 
C.elegans lifespan in a dose-dependent manner. A 2mg/mL RJ and 1mg/mL eRJ were 
selected as the optimum concentrations to prolong C. elegans lifespan. 
Several papers published that Royal Jelly also has anti-pathogen functions. In our 
experiment, worms were fed with E.coli OP50 as their regular food, and we questioned 
whether Royal Jelly’s anti-aging effect is dependent on inhibiting the growth of E.coli or 
attenuating the expression of its virulent factors expression. In order to answer this 
question, we cultured E.coli OP50 in LB medium with RJ/eRJ respectively and observed 
their growth curve. We observed that RJ/eRJ did not inhibit the E.coli OP50 growth at 
any bacterial growth phases, on the contrary, RJ/eRJ increased E.coli OP50 growth at the 
lag phase and log phase, which indicated that RJ/eRJ mediated lifespan extension did not 
act through its anti-pathogen effects (Figure 3.2). 
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Figure 3.1 RJ/eRJ extends C. elegans lifespan in a dose-dependent manner.   
Wild-type N2 worms were treated with RJ (A) or eRJ (B) at 0-5mg/mL. Each lifespan 
experiment was repeated at least three independent times with similar results. Quantative 
data and statistical analyses for the representative experiments are included in Table 1. 
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Table 1 The Lifespan of Wildtype Worms Stain at 25°C 
Stain   Mean±SE   Median   No.of Worms p value 
N2   12.97±0.32 13.00   52     
N2+ 0.4 mg/mL RJ* 13.02±0.30 13.00 
 
62 
 
0.320 
N2+ 1mg/mL RJ* 13.52±0.33 14.00 
 
52 
 
0.017 
N2+ 2mg/mL RJ* 15.52±0.23 16.00 
 
52 
 
<0.001 
N2 + 3mg/mL RJ* 14.39±0.22 15.00 
 
62 
 
<0.001 
N2+ 5mg/mL RJ* 12.64±0.43 13.00 
 
59 
 
0.543 
N2+ 0.4 mg/mL eRJ** 12.97±0.30 13.00 
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0.867 
N2+ 1mg/mL eRJ** 14.44±0.24 15.00 
 
45 
 
<0.001 
N2+ 2mg/mL eRJ** 14.07±0.20 14.00 
 
74 
 
0.001 
N2+ 3mg/mL eRJ** 13.95±0.22 14.00 
 
62 
 
0.003 
N2+ 5mg/mL eRJ** 12.68±0.40 13.00   50   0.699 
 
Note: Lifespan and standard error are shown in days. The lifespan experiments were 
repeated at least three times with similar results. And the data for representative 
experiments were shown. The lifespan data were analyzed using the log-rank test and p 
values for each individual experiment are shown. 
*Results presented in Figure 3.1 A     **Results presented in Figure 3.1 B 
 
 
45 
 
       
Figure 3.2 RJ/eRJ cannot affect E.coli OP50 growth.  E.coli OP50 were cultured 
with RJ/eRJ and OD600 were measured every hour to observe the growth curve. 
Experiment was repeated at least three independent times with similar results. 
Student t test showed p value was >0.05, quantitative data and statistical analyses 
were analyzed in excel. 
 
 
 
 
 
 
 
 
46 
 
3.2.2 RJ/eRJ barely Influences Reproductive Capacity and Motility of C. elegans. 
Given that RJ/eRJ could extend C. elegans lifespan, 2mg/mL RJ and 1mg/mL eRJ 
were selected as the optimum concentration to promote longevity. Next, we wondered 
whether RJ/eRJ affected the physiological indexes of C. elegans. In order to address this 
question, brood size (reproductive parameter) and motility were tested to check worms’ 
reproductive capacity and general fitness ability under RJ/eRJ supplementation. 
In the brood size test, N2 worms were treated with or without RJ/eRJ for two 
generations, afterwards the total offspring numbers of wild type worms were counted 
under each treatment. The results showed that the average of total offspring number was 
206 per worm in the control group, while the RJ/eRJ treated worms had the similar 
number when compared with the controls. This brood size result indicated that RJ/eRJ 
cannot affect worms’ total offspring quantity (Table 2).  
In the motility test, worms were treated with or without RJ/eRJ supplement for 
two generations, afterwards ten synchronized young adult worms from each treatment 
were transferred to non-seeded NGM plates and the body bends per minute were counted 
to check their moving ability. Our data showed that the average body bends per minute of 
one worm was 13.9 in the control group, while the RJ/eRJ treated worms had similar 
body bends times when compared with the controls. This result demonstrated that RJ/eRJ 
barely affected worms’ moving ability (Table 2). Taken together, our results suggested 
that RJ/eRJ mediated lifespan extension is not associated with any significant changes in 
reproductive capacity and motility of C. elegans. 
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Table 2. RJ/eRJ Supplementation Does Not Influence Motility and 
Reproductive Capacity of Caenorhabditis elegans at 25°C 
  control±SE 
RJ-Treated 
±SE 
eRJ-
Treated±SE p value 
Total No. of 
Worms  
Brood 
Size 206±23.6 194±18.9 203±24.7 0.37*, 0.84† 6*, 6†, 6ⱡ 
Motility 13.9±1.0 14.1±1.5 13.8±1.2 0.79*, 0.81† 10*, 10†, 10ⱡ 
 
Notes: These data represent the average of three independent trials for each test. 
*RJ-treated worms. 
†eRJ-treated worms. 
ⱡControl worms. 
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3.2.3 Supplementation of RJ/eRJ Modulateds C. elegans Lifespan through the IIS 
Cascade and DAF-16 
Our lifespan assays revealed that RJ/eRJ could extend C. elegans lifespan in a 
dose dependent manner. Next we want to know the molecular mechanism underlying this 
beneficial effect. It is well known that Insulin like signaling pathway (IIS pathway) is one 
of the most powerful pathways to regulate cell proliferation, metabolism, and longevity. 
We questioned whether RJ/eRJ mediated lifespan extension is dependent on the 
regulation of IIS pathway. First of all, we examined whether DAF-16, an important 
transcriptional factor of IIS pathway, was involved in the RJ/eRJ mediated anti-aging 
function. We treated null daf-16 (mgDf50) mutant worms with RJ (2mg/mL) and eRJ 
(1mg/mL) respectively and counted lifespan under 25°C. Our data showed that the mean 
lifespan of non-supplemented daf-16 deletion mutants was 6.85 days, and the mean 
lifespan of RJ and eRJ treatment was 6.91 days and 6.74 days respectively (Figure 3.3 A 
and B, and Table 3). This finding suggested that DAF-16 was required in RJ/eRJ 
mediated lifespan extension effect.  
Next, we tested whether DAF-2 and AGE-1, two major components of the IIS 
pathway, were required in RJ/eRJ mediated lifespan extension.. The mutant worms daf-2 
(e1370) were treated with RJ (2mg/mL) and eRJ (1mg/mL) respectively and lifespan was 
counted under 25°C. Our data showed that the mean lifespan of non-supplemented daf-2 
(e1370) mutants was 26.68 days, and the mean lifespan of RJ and eRJ treatment was 
26.99 days and 27.01 days respectively (Figure 3.3 C and Table 3). Similarly, the mean 
lifespan of non-supplemented age-1 (hx546) mutants was 27.08 days, and the mean 
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lifespan of RJ and eRJ treatment was 27.31 days and 27.00 days respectively (Figure 3.3 
D and Table 3). This result indicated that RJ/eRJ acted, at least in part, through the IIS 
pathway and DAF-16 to increase lifespan in C. elegans. 
Considering that the IIS pathway regulates lifespan in C. elegans by limiting 
DAF-16 nuclear trans-localization, we postulated that RJ/eRJ treatment might affect 
DAF-16 nuclear localization and transcriptional activities. In order to check the DAF-16 
nuclear localization, we examined subcellular localization of DAF-16 using transgenic 
worms overexpressing DAF-16::GFP (daf-16(mgDf47;xrls87)), which showed GFP 
signal in almost all somatic cells. Specifically, the DAF-16::GFP worms were 
supplemented with RJ/eRJ on NGM plates from the early L1 stage until day 2 adults. 
Afterwards the DAF-16::GFP signal in live worms (day 2 adults) was observed under a 
fluorescent microscope (Nikon AZ100). Unfortunately, we did not observed a significant 
increase of DAF-16-GFP in the nucleus after treatment of either RJ or eRJ (data not 
shown).  
In order to test how DAF-16 is modulated in RJ/eRJ mediated lifespan extension, 
we chose several DAF-16 target genes to check whether DAF-16 activity is influenced in 
the RJ/eRJ supplementation treatments. Wild type N2 worms were treated with or 
without RJ/eRJ for two generations and then the target genes expressions were tested by 
quantitative PCR methods. The result showed that the mRNA level of DAF-16 was not 
changed when compared to non-supplemented controls, but its target genes expressions 
were significantly affected. sod-3 is an important biomarker of DAF-16, which could 
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reflect the DAF-16 activity obviously. Moreover, mtl-1, C32H11.4 and F21F3.3 are 
DAF-16 target genes, which were selected in this experiment to check DAF-16’s 
transactivity. Based on our quantitative PCR results, the elevated expression of sod-3, 
mtl-1, F21F3.3 and reduced expression of C32H11.4 showed that DAF-16 activity was 
up-regulated in the RJ/eRJ supplementary treatments (Figure 3.3 E).  
Taken together, these findings suggested that RJ/eRJ treatment prolonged C. 
elegans lifespan, which were dependent on promoting transcriptional activities of DAF-
16 rather than improving the accumulation of DAF-16 in nuclei. 
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Figure 3.3 Both RJ and eRJ modulate Caenorhabditis elegans life span through 
the IIS pathway and DAF-16.  (A) daf-16(mgDf50) mutant worms were treated with 
2mg/mL RJ. (B) daf-16 (mgDf50) mutant worms were treated with 1mg/mL eRJ. (C) daf-
2(e1370) mutant worms were treated with either 2mg/mL RJ or 1mg/mL eRJ. (D) age-
1(hx546) mutant worms were treated with either 2mg/mL RJ or 1mg/mL eRJ. Each life-
span experiment was repeated at least three independent times with similar results. 
Quantitative data and statistical analyses for the representative experiments are included 
in Table 1. (E) The transcript levels of daf-16, sod-3, mtl-1, C32H11.4, F21F3.3,sir-2.1, 
and hcf-1 in N2 worms treated with and without 2mg/mL RJ or 1mg/mL eRJ were 
quantified using qRT–PCR. The data from three independent experiments were pooled to 
calculate the mean RNA level normalized to the internal control act-1. The standard 
errors of the mean (SEM) were shown. The normalized mean RNA level of controls in 
non-treated N2 worms were set to 1. *p < .05 compared with non-treated control. 
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Table 3. The Lifespan Data of Worms Strains at 25°C 
strain   Mean±SE   Median No. of Worms p value 
N2*   13.48±0.22   14.00   64     
N2+ 2mg/mL RJ* 15.57±0.28 
 
16.00 
 
58 
 
<0.001 
daf-16(mgDf50)* 7.21±0.23 
 
7.00 
 
84 
  daf-16(mgDf50) + 2mg/mL RJ* 6.74±0.26 
 
7.00 
 
65 
 
0.216 
N2** 
 
12.65±0.34 
 
13.00 
 
57 
  N2+ 1mg/mL eRJ** 14.40±0.37 
 
15.00 
 
45 
 
<0.001 
daf-16(mgDf50)** 6.85±0.23 
 
7.00 
 
72 
  daf-16(mgDf50) + 1mg/mL eRJ** 6.91±0.19 
 
7.00 
 
78 
 
0.874 
N2† 
 
12.64±0.30 
 
12.00 
 
80 
  N2+ 2mg/mL RJ† 14.29±0.35 
 
14.00 
 
80 
 
<0.001 
N2+ 1mg/mL eRJ† 13.86±0.31 
 
14.00 
 
92 
 
0.003 
daf-2(e1370)† 26.68±0.52 
 
27.00 
 
79 
  daf-2(e1370) + 2mg/mL RJ† 26.99±0.55 
 
27.00 
 
67 
 
0.726 
daf-2(e1370) + 1mg/mL eRJ† 27.01±0.48 
 
27.00 
 
80 
 
0.910 
N2ⱡ 
 
12.14±0.24 
 
12.00 
 
81 
  N2+ 2mg/mL RJⱡ 13.53±0.28 
 
14.00 
 
63 
 
<0.001 
N2 + 1mg/mL eRJⱡ 13.32±0.33 
 
13.00 
 
60 
 
0.001 
age-1(hx546)ⱡ 27.08±0.56 
 
27.00 
 
79 
  age-1(hx546) + 2mg/mL RJⱡ 27.31±0.50 
 
27.00 
 
89 
 
0.672 
age-1(hx546) + 1mg/mL eRJⱡ 27.00±0.42   27.00   78   0.179 
 
Notes: Life span and standard error are shown in days. The life-span experiments were 
repeated at least three times with similar results, and the data for representative 
experiments were shown. The life-span data were analyzed using the log-rank test 
and p values for each individual experiment were shown. 
*Results presented in Figure 3.3 A.               ** Results presented in Figure 3.3 B. 
†Results presented in Figure 3.3 C.                  ‡Results presented in Figure 3.3 D. 
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3.2.4 RJ/eRJ Mediated Lifespan Extension is Modulated by SIR-2.1, and HCF-1, as 
Well as FTT-2. 
As an important transcriptional factor, DAF-16 is tightly controlled by several co-
factors[73]. Next, we wondered whether DAF-16’s co-factors are involved in this RJ/eRJ 
mediated lifespan extension. Previous studies reported that SIR-2.1, HCF-1, and 14-3-3 
are important DAF-16 co-factors to modulate its transactivity. For instance, SIR-2.1 
physically associates with DAF-16 via FTT-2, a 14-3-3 protein of C. elegans, to promote 
the transactivation of DAF-16 under heat shock stress. Moreover, genetic and 
biochemical studies demonstrated that, associated with 14-3-3 proteins, HCF-1 and SIR-
2.1/SIRT1 physically interacted and antagonized each other to fine-tune target gene 
expressions DAF-16/FOXO and, in turn, to promot longevity and stress resistance[48, 62, 
153].  
First of all, we investigated whether SIR-2.1 was required in RJ/eRJ mediated 
lifespan extension. Deletion mutant worms sir-2.1 (ok434) were treated with RJ/eRJ to 
carry out lifespan assays. Our results showed that the mean lifespan of RJ/eRJ treatments 
were 12.82 days and 12.74 days. As compared to the mean lifespan of non-supplemented 
controls (12.82 days), we found out that RJ/eRJ cannot extend sir-2.1 (ok434) mutants 
lifespan. This result suggested that SIR-2.1 was required in RJ/eRJ mediated lifespan 
extension (Figure 3.4 A and B and Table 4). 
Next, we tested whether RJ/eRJ modulated C. elegans lifespan dependent on 
another two factors: 14-3-3 and HCF-1. Deletion mutant worms ftt-2 (n4426) and hcf-1 
(ok559) were treated with 2mg/mL RJ or 1mg/mL eRJ, and lifespan assays were carried 
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out under 25°C. For the ftt-2 (n4426) mutant worms, the mean lifespan of RJ/eRJ 
treatments were 11.57 days and 11.51 days. As compared to mean lifespan of genotype 
matched non-supplemented controls (11.67 days), we found out that RJ/eRJ cannot 
extend ftt-2 (n4426) mutants lifespan (Figure 3.4 C and D and Table 4). Similarly, RJ/eRJ 
supplementation failed to extend hcf-1 (ok559) mutant worms’ lifespan. Our data showed 
that the mean lifespan of RJ/eRJ treatments were 15.79 days and 15.75 days, while the 
mean lifespan of non-supplemented controls were nearly the same (15.94 days). These 
results indicated that besides SIR-2.1, HCF-1, and 14-3-3 were also required in RJ/eRJ 
mediated lifespan extension (Figure 3.4 E and F and Table 4). 
Considering that either overexpression of SIR-2.1 or attenuation of HCF-1 can 
extend C.  elegans life span, we wondered whether RJ/eRJ supplementation extended 
lifespan by altering the expression of SIR-2.1 and HCF-1. To address this concern, we 
employed qPCR to measure the expression levels of sir-2.1 and hcf-1 with or without 
RJ/eRJ supplementation. Our data showed that the mRNA levels of both sir-2.1 and hcf-
1were not significantly altered when compared with controls (Figure 3.3 E). Overall, our 
findings suggested that RJ/eRJ modulated lifespan dependent, at least in part, on the 
sophisticated interplays of DAF-16, SIR-2.1, HCF-1, and 14-3-3 proteins. 
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Figure 3.4 The RJ/eRJ requires SIR-2.1, HCF-1, and FTT-2 to 
prolong Caenorhabditis elegans lifespan.  (A) The sir-2.1 (ok434) mutant worms 
were treated with 2mg/mL RJ. (B) The sir-2.1(ok434) mutant worms were treated with 
1mg/mL eRJ. (C) The ftt-2 (n4426) mutant worms were treated with 2mg/mL RJ. (D) 
The ftt-2(n4426) mutant worms were treated with 1mg/mL eRJ. (E) The hcf-1 (ok559) 
mutant worms were treated with 2mg/mL RJ. (F) The hcf-1 (ok559) mutant worms were 
treated with 1mg/mL eRJ. Each life-span experiment shown here was repeated at least 
three independent times with similar results. Quantitative data and statistical analyses for 
the representative experiments are included in Table 4. 
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Table 4. The Lifespan Data of Worms Strains at 25°C 
strain     Mean±SE Median No. of Worms p value 
N2*     12.21±0.28 12.00   86     
N2 + 2mg/mL RJ* 
 
13.87±0.30 14.00 
 
62 
 
0.001 
N2 + 1mg/mL 
eRJ* 
 
13.28±0.28 13.00 
 
81 
 
0.015 
sir-2.1 (ok434) * 
 
12.82±0.19 13.00 
 
68 
  sir-2.1 (ok434) + 2mg/mL RJ* 12.82±0.19 13.00 
 
84 
 
0.690 
sir-2.1 (ok434) + 1mg/mL 
eRJ* 12.74±0.24 13.00 
 
62 
 
0.630 
N2† 
  
12.56±0.20 13.00 
 
121 
  N2 + 2mg/mL RJ† 
 
14.57±0.28 15.00 
 
58 
 
<0.001 
N2 + 1mg/mL 
eRJ† 
 
14.40±0.37 15.00 
 
55 
 
<0.001 
ftt-2 (n4426)† 
 
11.67±0.29 12.00 
 
124 
  ftt-2 (n4426) + 2mg/mL RJ† 11.57±0.52 13.00 
 
51 
 
0.795 
ftt-2 (n4426) + 1mg/mL eRJ† 11.51±0.30 12.00 
 
77 
 
0.318 
N2ⱡ 
  
12.21±0.28 12.00 
 
86 
  N2 + 2mg/mL RJⱡ 
 
13.87±0.30 14.00 
 
62 
 
0.001 
N2 + 1mg/mL 
eRJⱡ 
 
13.28±0.28 13.00 
 
81 
 
0.015 
hcf-1 (ok559)ⱡ 
 
15.94±0.42 15.00 
 
65 
  hcf-1 (ok559) + 2mg/mL RJⱡ 15.79±0.57 16.00 
 
52 
 
0.977 
hcf-1 (ok559) + 1mg/mL eRJⱡ 15.75±0.43 15.00   48   0.629 
 
Notes: Life span and standard error were shown in days. The lifespan experiments were 
repeated at least three times with similar results, and the data for representative 
experiments were shown. The lifespan data were analyzed using the log-rank test 
and p values for each individual experiment were shown. 
*Results presented in Figure 3.4 A and B.           †Results presented in Figure 3.3 C and D. 
‡Results presented in Figure 3.4 E and F. 
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3.3 Discussion 
Aging causes the physiological decline and increases the risk of disease, which 
brings a challenging question to society and encourages scientists to look for efficient 
methods to slow down the development of age related disorders. Accumulation evidences 
suggested that neutraceuticals, such as cranberry, cocoa, green tea, and herbal medicines, 
provide a variety of health benefits to relay the aging process[91]. Several research labs 
published that Royal Jelly, a bee product, has the lifespan extension function in C. 
elegans model and alleviates type II diabetes disease in murine model. However, the 
detailed molecular mechanism of Royal Jelly’s anti-aging effects remains elusive[103]. 
 In this study, we utilized C. elegans as a model to investigate Royal Jelly’s anti-
aging function, we observed that regular Royal Jelly (RJ) and enzyme treatment Royal 
Jelly (eRJ) could extend C. elengans lifespan in a dose dependent manner. Moreover, 
RJ/eRJ did not affect C. elegans normal physiological traits, such as reproductive ability 
and motility. Our genetic analysis indicated that Insulin like Signaling (IIS) pathway and 
its important component DAF-16 were required in RJ/eRJ mediated lifespan extension. 
Meanwhile, three DAF-16 co-factors, SIR-2.1, HCF-1, and 14-3-3, were also involved in 
this beneficial effect. Our studies proposed a genetic model to elucidate the molecular 
basis of RJ/eRJ’s pro-longevity function. Under the supplementation of RJ/eRJ, SIR-2.1, 
HCF-1, and 14-3-3 are activated to fine-tune DAF-16 activity, and the sophisticated 
interplay of these four proteins could regulate the expression of DAF-16 target genes to 
promote animals’ health aging.  
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Figure 3.5 RJ/eRJ depends on the interplay of DAF-16, SIR-2.1, HCF-1 and 14-
3-3 to modulate C. elegans lifespan.  C. elegans lead a regular lifespan when treated 
with regular food (E. coli OP50), however, RJ/eRJ supplementation may trigger the 
regulatory interplays of DAF-16, SIR-2.1, HCF-1, and 14-3-3 to fine-tune DAF-16 
activity in the nucleus autonomously. This sophisticated modulation induces a series of 
DAF-16 target genes expressions to extend C. elegans lifespan. 
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At the beginning, wild type worms were treated with different concentrations of 
RJ/eRJ, ranging from 0 to 5 mg/mL, to select an optimum concentration for lifespan 
extension by comparing their mean lifespans. The lowest concentration (0.4 mg/mL) and 
highest concentration (5mg/mL) barely influenced mean lifespan of wild type worms, but 
the concentration of 1 to 3 mg/mL RJ/eRJ extended C. elegans lifespan significantly. Our 
results indicated that RJ/eRJ extended C. elegans lifespan in a dose dependent manner. In 
consideration that Royal Jelly is composed of 67% water, 12.5% crude protein, 11% 
simple sugars, and a relatively high amount (5%) of fatty acids[154], it is conceivable 
that the effective pro-longevity factors are included in proteins and fatty acids parts. 
Therefore the lower concentration (0.4 mg/mL) does not contain enough functional 
proteins to prolong worms’ mean lifespan. In contrast, even the 5mg/mL Royal Jelly 
includes high concentration of proteins and fatty acid,  the results showed that the 
5mg/mL Royal Jelly shortened worms’ lifespan. It is well known that many natural 
substances used for therapeutic benefit have the potential to have their benefits eclipsed 
by toxic effects at high doses[155].  Morever, it is reported that high concentration of 
sugar could shorten worms’ lifespan. In agreement with this, we realized that the 5 
mg/mL RJ/eRJ contains nearly 1mg/mL sugar, which might be the reason that higher 
concentration of RJ/eRJ cannot prolong the lifespan.  
Next, we wondered whether there is any difference of anti-aging effect between 
the two types of Royal Jelly powders in our research. The manufacturing process of the 
two powders are almost the same: after the filtration, disinfection, lyophilization, and 
pulverization steps, fresh Royal Jelly is processed to powder, which makes Royal Jelly 
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easy to be stored and utilized in experiments. The only difference between the two types 
of Royal Jelly is the proteases treatment, which decomposes large proteins into amino 
acids and peptides. The aim of this enzyme treatment is to decrease the large-proteins 
induced allergic properties but still retain bioactive functions. In order to prepare the 
RJ/eRJ paltes, the RJ/eRJ powders were dissolved in sterile distilled water and vortex 
vigorously to dissolve adequately.  Noticeably, a lot of floating bubbles were observed on 
the surface of RJ powder mixture, but this phenomenon was not observed in eRJ mixture, 
which indicated that the composition of RJ and eRJ were different and the bubbles in RJ 
might be cause by certain large proteins. Intriguingly, our lifespan results showed that 
both RJ and eRJ increased C. elegans lifespan, but the optimum concentrations of RJ and 
eRJ were different (2mg/mL RJ and 1mg/mL eRJ, respectively) (figure 3.1 and table 1). 
This finding suggested that the enzyme digestion might decrease the toxicity of certain 
RJ and, in turn, alter bioactivity and improve the immune system of C. elegans. As a 
result, the optimized concentration of eRJ for lifespan extension is reduced to 1mg/mL, 
only half of RJ concentration.  However, there is also a problem cannot be ignored, 
although the enzyme treatment decreased the large-proteins induced allergic response in 
eRJ supplementation, the mean lifespan of 2mg/ml RJ (15.52 days) was 1.08 days longer 
than 1mg/mL eRJ treatment(14.44 days). This data demonstrated that certain large RJ 
proteins, which were deleted by protease in eRJ powder, might have the beneficial effects 
in anti-aging function. Further experiments need to be conducted to investigate the 
differences between RJ and eRJ’s pro-longevity effects.  
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Overall, our lifespan results indicated that RJ/eRJ extended C. elegans lifespan in 
a dose dependent manner, and the optimum concentrations of lifespan extension were 
determined to be: 2mg/mL RJ and 1mg/mL eRJ, which were used in the further 
experiments to investigate the molecular mechanism underlying this beneficial effect. 
Moreover, RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, respectively) did not affect worms’ 
physiological indexes, such as reproductive capacity and mobility, which indicated that 
RJ/eRJ was safe to be consumed as a functional product. Therefore, it is possible that 
RJ/eRJ might be a beneficial nutraceutical for human consumption because of its lifespan 
extension function and safety.   
Given that RJ/eRJ extended C. elegans lifespan, we further investigated the 
molecular mechanism underlying this beneficial effect. It is well known that Insulin Like 
Signaling pathway (IIS) is a master regulator of longevity, and DAF-16 was an important 
component at downstream of IIS pathway. Honda’s research group published that 
IIS/DAF-16 was required in Royal Jelly’s anti-aging function. In agreement with their 
study, our genetic results also showed that IIS/DAF-16 was critical in RJ/eRJ’s anti-aging 
function, because both RJ/eRJ cannot extend the mean lifespan of daf-2 deletion mutants, 
age-1 deletion mutants and daf-16 deletion mutants’ lifespan respectively (Figure 3.3). 
As an important transcriptional factor of IIS, DAF-16 plays a key role in regulating 
proliferation, metabolism, and longevity. Morever, DAF-16’s activity is known to be 
regulated by post-translational modifications, nuclear/cytoplasmic translocation and is 
also associated with transcriptional co-factors[156]. We further investigated whether 
RJ/eRJ mediated lifespan extension was dependent on modulating the activity of DAF-16. 
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Previous studies have demonstrated that reduction of IIS activates DAF-16 by 
increasing its nuclear translocation to extend lifespan. Our genetic results suggested that 
RJ/eRJ mediated lifespan extension, at least in part, acted through IIS pathway. This 
finding indicated that under the supplementation of RJ/eRJ, increased amount of DAF-16 
might translocate into the nuclear. Unfortunately, we did not observe the florescence 
signal in RJ/eRJ treated DAF-16:GFP worms, indicating that RJ/eRJ barely affected 
DAF-16 nuclear translocation. There are two possibilities to explain this result. First, it 
has been reported that many obvious DAF-16 nuclear translocations are caused by severe 
stresses or the alteration of crucial genes alteration. In comparison, Royal Jelly is a 
functional food and induces mild changes in C. elegans growth process, which are similar 
to a normal physiological level. As a result, this moderation increases of DAF-16 nucleus 
translocation is not strong enough to be observed under regular fluorescence microscopy.  
Another possibility is RJ/eRJ increases the transactivity of DAF-16 rather than promoting 
DAF-16’s nucleus translocation. It is well known that DAF-16 nucleus translocation is 
very important for DAF-16 activation, but translocation of DAF-16 into nucleus is not 
sufficient to stimulate its transcriptional activity. Therefore our hypothesis is that 
although RJ/eRJ did not elevate DAF-16’s nuclear translocation amount, RJ/eRJ still 
increased DAF-16 activity to modulate the expression of its target genes. Indeed, the 
changes of DAF-16 target genes expressions are much more sensitive to be detected by 
using quantitative PCR method. . Our quantitative PCR experiments showed that RJ/eRJ 
did not change DAF-16 gene expression, but significantly influenced the expression of its 
target genes (sod-3, mtl-1, F21F3.3 and C32H11.4). Specifically, the expression of sod-3 
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and mtl-1 (two important biomarkers of DAF-16) were increased more than two folds in 
RJ/eRJ treated worms. This result indicated that DAF-16 activity was up-regulated under 
RJ/eRJ supplementation. Although the increased DAF-16 translocation is not detected in 
our research, the DAF-16 target gene expression results confirmed that RJ/eRJ anti-aging 
function acts through increasing the DAF-16 activity (Figure 3.3 E). 
DAF-16/FOXO has been reported to play an essential role in regulating cell 
proliferation and maintaining the energy homeostasis in organisms. DAF-16 activity is 
tightly controlled by genes and pathways, the regulatory specificity and precision of 
DAF-16 is critical to ensure several biological processes. It is reported that dysregulation 
of FOXO1 could cause a series of diseases, such as hyperglycemia and glucose 
intolerance[157]. As an important transcription factor, DAF-16 functions to regulate 
many important biological processes by modulating expressions of many genes, and the 
regulation of DAF-16’s activity depends on the balance of a complicated interplay among 
several co-factors. It is reported that SIR-2.1, HCF-1 and 14-3-3, three important DAF-16 
co-factors, have physical interactions with DAF-16 to modulate its activity. Berdichevsky 
and his colleagues reported that under heat shock stress, 14-3-3 functioned as a bridging 
protein to link SIR-2.1 with DAF-16, this interplay induced the expression of DAF-16 
target genes and thereby extended the survival of C. elegans under stress[48]. Another 
important co-factor is HCF-1, which plays a key role in transcriptional processes and cell 
cycle control. Li and colleagues reported that HCF-1 is also a putative longevity 
determinant factor to modulate DAF-16 activity, independently from IIS. Their findings 
revealed that the reduction of HCF-1 increased DAF-16 activity to extend lifespan[49]. 
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Moreover, their follow-up research suggested under the reduction of IIS, HCF-1, SIR-2.1, 
and 14-3-3 proteins might modulate DAF-16 activity in the nucleus to respond to aging 
and stress[65]. In our study, the results provided more evidence to confirm their results 
and underscored the significance of these four proteins regulatory interplays in dietary 
aging intervention. Our genetic results showed that besides IIS/DAF-116, DAF-16 co-
factors- SIR-2.1, 14-3-3, and HCF-1- were also required to modulate DAF-16 activity in 
RJ/eRJ mediated aging intervention. Additionally, the quantitative PCR results showed 
that RJ/eRJ did not affect the expression of sir-2.1 and hcf-1 genes. In considering that 
overexpression of SIR-2.1 and down-regulation of HCF-1 could increase the C. elegans 
lifespan respectively, our results indicated that RJ/eRJ mediated pro-longevity effects 
were dependent on promoting the interplays of SIR-2.1, HCF-1, and DAF-16 to modulate 
the transactivity of DAF-16 rather than influencing the expression of hcf-1 and sir-2.1. 
Moreover, the expression of C32H11.4 and F21F3.3 (target genes of both HCF-1 and 
DAF-16[49]) in C. elegans were changed by RJ/eRJ supplementation, which further 
confirmed our genetic data that DAF-16 and its co-factors were required in RJ/eRJ 
mediated aging intervention. 
Numerous studies have demonstrated that Royal Jelly is a functional nutraceutical 
and has many beneficial effects, such as anti-fatigue effects, stimulates bone formation, 
regulates immune responses, and protects liver from virus induced damage in animal 
models[99-101, 158] In honey bees, genetically identical honey bee larvae develop into 
either worker bees or queen bees depending on exposure to Royal Jelly. Based on the 
composition of Royal Jelly, nearly half dry mass of Royal Jelly is protein, which might 
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be the most powerful regulator to determine a honey bee’s fate and lifespan. It is possible 
that Royal Jelly function proteins might be beneficial to other animals through food 
intake. Our research highlights the pro-longevity properties of RJ and reveals the 
molecular mechanism of Royal Jelly’s beneficial effects, which might also be applied to 
mammal systems, including humans.  It is conceivable that Royal Jelly supplementation 
functions as aging-intervention method for humans to promote healthy aging and delay 
the age-related disorders, further clinical research remains to be conducted to confirm our 
hypothesis.  
It is well known that IIS pathway, DAF-16/FOXOs, SIR-2.1/SIRT1, HCF-1 and 
14-3-3 are evolutionarily conserved from C. elegans to mammals, our RJ/eRJ 
supplementary C. elegans model might be implicated mammal models to further study 
the genetic network of aging. In addition to SIR-2.1, HCF-1 and 14-3-3, other DAF-16 
co-factors might also involve in the RJ/eRJ mediated pro-longevity function, for example, 
SMK-1, BAR-1, et al[47, 159]. Moreover, besides IIS pathway, other pathways might 
also be required in Royal Jelly mediated beneficial effects, such as JNK pathway, TOR 
pathway, and P38 MAPK pathway [160-162]. Further research will be carried out in the 
future to help us better understand the detailed mechanism of aging process.  
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CHAPTER FOUR : THE ANTI-STRESS CAPABILITY OF ROYAL JELLY 
SUPPLEMENTATION 
4.1 Introduction 
In Chapter three, our results demonstrated that RJ/eRJ extended C. elegans 
lifespan without affecting the physiological indexes. This beneficial effect acted through 
IIS/DAF-16 and its three important co-factors, SIR-2.1, HCF-1, and 14-3-3, which are 
essential proteins to regulate metabolism, proliferation, and longevity in C. elegans. 
Cumulative evidence indicated that the lifespan extension benefits are often correlated 
with increased stress resistant capability[163, 164]. Interestingly, our quantitative PCR 
results showed that the supplementation of Royal Jelly could affect the expression levels 
of certain stress response genes, such as sod-3, mtl-1, C32H11.4, and F21F3.3. Moreover, 
DAF-16 regulates numerous stress response genes, such as anti-oxidant and protein 
turnover genes, to maintain the protein homeostasis in cells. In addition to DAF-16, its 
three co-factors, SIR-2.1, HCF-1, and 14-3-3 are also reported to be involved in stress 
response and adaptions. It is highly possible that RJ/eRJ supplementation might also have 
anti-stress functions. In order to confirm this hypothesis, stress assays were conducted to 
investigate whether RJ/eRJ could protect C. elegans from a variety of stressors, including 
oxidative stress, UV irradiation, and heat shock stress.  
Environmental stresses and normal cell metabolism could form Reactive Oxygen 
Species (ROS), which may result in significant damage to cell components[165]. In 
response to this damage, cells are equipped with internal protective systems, such as 
antioxidant molecules, DNA repair pathways, and chaperones, to repair the destructed 
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DNA and proteins to maintain cellular homeostasis[166]. However, under persisting 
stress conditions or in the aging cells, the oxidative damages are accumulated, and the 
cells’ repair capacity is declined, which in turn increases cellular proteotoxicity to 
accelerate the aging process and cause several diseases, such as neurodegenerative 
diseases, cancer, and premature aging[149]. 
Several labs have demonstrated that some nutraceuticals have pro-longevity effect 
as well as stress resistance capacity. For example, resveratrol could affect SIR-
2.1/SIRT1’s activity to extend lifespan and increase resistance to oxidative stress and UV 
irradiation in animal models[96]. Similarly, cranberry influenced Insulin Signaling 
Pathway to protect C. elegans from thermal stress and slow down the aging process[123]. 
Our research revealed that RJ/eRJ also had the anti-stress functions to protect C. elegans 
from oxidative stress, UV irradiation and heat shock. Moreover, this stress resistance 
beneficial effect was dependent on, at least in part, the regulation of DAF-16, SIR-2.1, 
HCF-1, and 14-3-3.  
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4.2 Results 
4.2.1 Supplementation of RJ/eRJ promotes C. elegans stress resistance to 
oxidative stress, UV irradiation, and heat shock stress 
Extended longevity is often genetically correlated with increased resistance 
against various stressors, including oxidative stress, heat shock, UV irradiation, osmosis 
stress, and pathogen infection. In chapter three, we demonstrated that RJ/eRJ 
supplementation had lifespan extension benefit. Herein, we want to investigate whether 
RJ/eRJ supplementation could protect worms against stresses. 
First of all, oxidative stress was tested to investigate whether RJ/eRJ could protect 
C. elegans from oxidative damages. Wild type worms (N2) were treated with or without 
RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, respectively) for two generations (5 days) under 
25°C. Then the synchronized L4/young adult worms were transferred to NGM plates 
containing 5mM paraquat to observe survival. Basically, paraquat is an organic 
compound which can produces superoxide anions to induce redox activity. In our 
research, paraquat was used to create oxidative stress environment. At the same time, N2 
worms treated with or without RJ/eRJ on regular NGM plates (no paraquat) were set as a 
system control.  
Based on our observation, on the second day, the survival rate of controls was 
lower than 80%, whereas nearly 98% of RJ/eRJ treated worms were still alive. On the 
fourth day, more than 50% of control worms were already dead, but the RJ/eRJ treated 
worms’ survival rate was more than 80%. Surprisingly, on the sixth day, the survival rate 
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of RJ/eRJ treatment was more than two times longer than the survival rate of the controls. 
This experiment was continued until day 10, and the data was analyzed to compare the 
differences between each treatment (Figure 4.1 A and B). This result indicated that 
RJ/eRJ could protect C. elegans from oxidative stress. 
Next, UV irradiation stress was tested to study whether RJ/eRJ could protect C. 
elegans from UV-light induced DNA damage. C. elegans were treated with or without 
RJ/eRJ for two generations before exposure under UV irradiation at 0.05J/cm
2
 for 20 
seconds.  After treated with UV irradiation, C. elegans were cultured at 25°C to observe 
survival for 10 days. Meanwhile, N2 worms treated with or without RJ/eRJ on regular 
NGM lifespan plates (no UV irradiation) were set up as a system control to check 
whether the whole system works well. The UV irradiation result showed that on the 
second day, the survival rate of control group was lower than 80%, whereas nearly 98% 
RJ/eRJ treated worms were still alive. On the fourth day, the survival rate of control 
group dropped to nearly 50%; by contrast, the RJ/eRJ treated worms survival rate was 
still 80%. Noticeably, on the sixth day, only less than 20% of control worms were still 
alive, and the RJ/eRJ treated worms survival rate was around two to three times higher 
when compared with the rate of the control group (Figure 4.1 C and D). This result 
suggested that RJ/eRJ supplementation increased C. elegans UV irradiation resistance. 
Heat shock stress was tested to investigate whether RJ/eRJ could protect C. 
elegans from thermal-induced proteins damage. Worms were treated with or without 
RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, respectively) for two generations at 25°C (5 days). 
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Then the synchronized L4/young adult worms were heat shocked for three hours at 35°C 
and returned back to 25°C. Survivals were observed for ten days to compare the 
difference of each treatment. Meanwhile, N2 worms treated with or without RJ/eRJ on 
NGM lifespan plates (no heat shock) were set up as a system control. On the second day, 
more than 70% of the heat shocked control worms were dead, but the RJ/eRJ worms’ 
survival rates were more than 80% (in RJ treatment heat shocked) and 60% (in eRJ 
treatment heat shocked). On the fourth day, the survival rate of heat shocked control 
worms was less than 30%, while the survivals of RJ/eRJ treated worms were nearly two 
to three fold higher comparing with that of the control group. Interestingly, the results of 
day 6, 8 and 10 showed the same trend that RJ/eRJ treated worms survival percentages 
were higher than those of the control group (Figure 4.1 E and F). This result 
demonstrated that RJ/eRJ protected C. elegans against heat shock stress.  
Taken together, our anti-stress assays indicated that RJ/eRJ supplementation 
protected C. elegans against oxidative stress, UV irradiation, and heat shock stress. 
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Figure 4.1 The RJ/eRJ treatment results in a promoted stress resistance to 
specific environmental stimuli.  (A) The RJ (2mg/mL) treated N2 worms showed 
prolonged survival in response to 5mM paraquat compared with non-treated worms. (B) 
The eRJ (1mg/mL) treated N2 worms showed prolonged survival in response to 5mM 
paraquat compared with non-treated worms. (C) The RJ (2mg/mL) treated N2 worms 
showed elevated survival after ultraviolet (UV) irradiation compared with non-treated 
worms. (D) The eRJ (1mg/mL) treated N2 worms showed elevated survival after UV 
irradiation compared with non-treated worms. (E) The RJ (2mg/mL) treated N2 worms 
exhibited increased survival after 3 hours at 35°C compared with non-treated worms. (F) 
The eRJ (1mg/mL) treated N2 worms exhibited increased survival after 3 hours at 35°C 
compared with non-treated worms. Each stress assay was repeated at least three times. 
“Fraction alive” indicates the average survival among the multi-replicates and error bars 
represent the standard deviation. p value was calculated using Student’s t test. *p < .05 
compared with corresponding control. Each of the stress assays was repeated at least 
three independent times with similar results. 
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4.2.2 RJ/eRJ may promote stress resistance of C. elegans through, at least in part, 
modulating the interplays of DAF-16, SIR-2.1, HCF-1, and 14-3-3 proteins 
Given that the molecular mechanisms behind lifespan elongation and stress 
resistance may not overlap, we questioned whether this RJ/eRJ mediated stress tolerance 
may also require, at least partially, the interplays of DAF-16, SIR-2.1, HCF-1 and 14-3-3 
proteins.  
In this study, we treated the four mutant worms, daf-16 (mgDf50), sir-2.1 (ok434), 
hcf-1 (ok599), and ftt-2 (n4426) with or without RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, 
respectively) for two generations. Then mutant worms were exposed to oxidative stress, 
UV irradiation, and heat shock stress to observe their stress resistant capability. The 
differences in survival rates were compared between RJ and eRJ treatments with controls 
in each stress response to analyze whether RJ/eRJ mediated stress responses share the 
same genetic mechanism with its pro-longevity function.  
In the oxidative stress experiment, RJ/eRJ cannot protect four mutant worms 
under paraquat treatment, which indicated that DAF-16, SIR-2.1, HCF-1, and 14-3-3 
were required in RJ/eRJ mediated anti-oxidative stress response. Interestingly, it is worth 
noting that the p value of RJ/eRJ treatment versus control group in daf-16 (mgDf50) and 
hcf-1 (ok599) were just beyond the statistical significance (p<0.05), but very close to it 
(Table 5). These data indicated that, besides DAF-16, other transcriptional factors might 
also be required in RJ/eRJ mediated anti-oxidative stress.  
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In the UV irradiation stress assays, our data showed that RJ/eRJ cannot protect 
daf-16 (mgDf50) and sir-2.1 (ok434) mutant worms against UV irradiation, but RJ/eRJ 
can still increase the survival rate of hcf-1 (ok599) and ftt-2 (n4426) mutant worms (Table 
5), which indicated that RJ/eRJ required DAF-16 and SIR-2.1, but not HCF-1 and 14-3-3 
to protect C. elegans against UV irradiation stress.  
In the heat shock stress assays, our results showed that DAF-16, SIR-2.1 and 14-
3-3 were involved in RJ/eRJ mediated anti-heat shock stress. However, HCF-1 was not 
required because RJ/eRJ can still protect hcf-1 (ok599) mutant worms from heat shock 
stress. Intriguingly, there is a problem cannot be ignored, the p values of RJ/eRJ 
treatment versus non-treatment controls in daf-16 (mgDf50) and sir-2.1 (ok434) mutant 
worms were just beyond the statistical significance (p<0.05), but very close to it (Table 5). 
These data also implied that besides DAF-16, other regulators might also be required in 
RJ/eRJ mediated heat shock stress responses. 
Overall, our findings suggested that RJ/eRJ may promote stress resistance of C. 
elegans through, at least partially, modulating the interplays of DAF-16, SIR-2.1, HCF-1, 
and 14-3-3 proteins.  
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Table 5. The Survival Time of Various Worm Strains under Stresses 
  strain   Mean±SE Median 
No.of 
worms p value 
Oxidative daf-16 (mgDf50) 3.10±0.16 3.00 73 
 Stress daf-16 (mgDf50) + 2mg/mL RJ 3.43±0.19 3.00 72 0.050 
 
daf-16 (mgDf50) + 1mg/mL eRJ 3.40±0.18 3.00 75 0.051 
      
 
sir-2.1 (ok434) 
 
3.73±0.22 4.00 70 
 
 
sir-2.1 (ok434) + 2mg/mL RJ 3.96±0.24 4.00 74 0.471 
 
sir-2.1 (ok434) + 1mg/mL eRJ 3.72±0.21 4.00 75 0.927 
      
 
hcf-1(ok559) 
 
5.95±0.29 6.00 83 
 
 
hcf-1(ok559) + 2mg/mL RJ 6.92±0.31 7.00 76 0.055 
 
hcf-1(ok559) + 1mg/mL eRJ 6.93±0.29 7.00 75 0.057 
      
 
ftt-2 (n4426) 
 
3.77±0.24 4.00 68 
 
 
ftt-2 (n4426) + 2mg/mL RJ 4.00±0.24 4.00 84 0.399 
 
ftt-2 (n4426) + 1mg/mL eRJ 4.25±0.26 4.00 73 0.186 
      
Ultraviolet daf-16 (mgDf50) 2.94±0.66 3.00 63 
 Irradiation daf-16 (mgDf50) + 2mg/mL RJ 3.17±0.08 3.00 86 0.177 
 
daf-16 (mgDf50) + 1mg/mL eRJ 3.18±0.09 3.00 76 0.181 
      
 
sir-2.1 (ok434) 
 
3.57±0.11 4.00 74 
 
 
sir-2.1 (ok434) + 2mg/mL RJ 3.67±0.11 4.00 78 0.474 
 
sir-2.1 (ok434) + 1mg/mL eRJ 3.77±0.13 4.00 74 0.138 
 
 
hcf-1(ok559) 
 
5.07±0.29 5.00 86 
 
 
hcf-1(ok559) + 2mg/mL RJ 6.28±0.28 6.00 104 0.012 
 
hcf-1(ok559) + 1mg/mL eRJ 6.02±0.32 6.00 89 0.039 
 
 
ftt-2 (n4426) 
 
4.64±0.27 4.00 67 
 
 
ftt-2 (n4426) + 2mg/mL RJ 5.68±0.32 5.00 56 0.022 
 
ftt-2 (n4426) + 1mg/mL eRJ 5.75±0.30 5.00 56 0.016 
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Table 5 (continued). The Survival Time of Various Worm Strains under Stresses 
  strain   Mean±SE Median No.of worms p value 
Heat daf-16 (mgDf50) 2.63±0.11 3.00 111 
 Shock daf-16 (mgDf50) + 2mg/mL RJ 2.95±0.12 3.00 87 0.062 
 
daf-16 (mgDf50) + 1mg/mL eRJ 2.97±0.16 3.00 68 0.063 
 
sir-2.1 (ok434) 3.35±0.31 3.00 83 
 
 
sir-2.1 (ok434) + 2mg/mL RJ 4.35±0.37 4.00 69 0.051 
 
sir-2.1 (ok434) + 1mg/mL eRJ 4.19±0.34 4.00 74 0.054 
 
hcf-1(ok559) 4.25±0.36 4.00 94 
 
 
hcf-1(ok559) + 2mg/mL RJ 5.76±0.38 6.00 70 0.035 
 
hcf-1(ok559) + 1mg/mL eRJ 5.55±0.39 6.00 78 0.046 
 
ftt-2 (n4426) 3.64±0.37 4.00 72 
 
 
ftt-2 (n4426) + 2mg/mL RJ 4.36±0.40 4.00 81 0.166 
  ftt-2 (n4426) + 1mg/mL eRJ 3.89±0.33 4.00 94 0.782 
 
Notes: The life span and standard error were shown in days. The life-span experiments 
were repeated at least three times with similar results, and the data for representative 
experiments were shown. The life-span data were analyzed using the log-rank test 
and p values for each individual experiment are shown. SE = standard error. 
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4.3 Discussions 
Numerous studies showed that lifespan extension is often correlated with 
increased stress resistance[167]. Genetic manipulations in Insulin Signaling Pathways as 
well as feeding and dietary restrictions affected lifespan and stress resistance significantly. 
For instance, the deletion of daf-2 were found to double the lifespan of wild type worms 
and resistant to several stressors, such as oxidative and thermal stresses[168]. Another 
example of this genetic manipulation is eat-2 deletion mutant, which has a feeding 
problem during growth and has also showed long-lived and anti-stress phenotypes. 
However, the molecular mechanism underlying the link between pro-longevity and stress 
resistance is still unclear. One possible reason might be that some pro-longevity factors 
not only have the lifespan extension function but also protect organisms from the 
damages caused by stresses.  
In our daily life, we are always exposed to complex mixtures of various 
environmental pollutants, which are produced by natural and human made sources such 
as combustion, construction, agriculture and so on. Some chemicals or pollutants could 
cause toxic effects to impair human’s health. The accumulation of these damages could 
accelerate the aging process and increase the risk of cancer, diabetes, obesity, and 
neurodegenerative diseases. Several pieces of evidence hint that there might be a link 
between aging, stress, and age-related diseases[169]. 
Several aging research labs revealed that some functional nutraceuticals had anti-
stress function. Ungvari and Jin published that resveratrol, a popular pro-longevity 
product, had the antioxidant effect and thereby alleviated Parkinson’s disease[170]. 
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Moreover, Guha and Guo reported that cranberry, a healthy fruit, possessed the heat 
shock resistant capability as well as lifespan extension. Moreover, it can delay the onset 
development of Alzheimer’s disease[123]. In addition, numerous publications reported 
that nutraceuticals have lifespan extension and stress resistance, which further confirmed 
the link between pro-longevity and anti-stress functions. 
In chapter three, our results demonstrated that RJ/eRJ had pro-longevity function 
and explained the molecular mechanism underlying this beneficial effect. Noticeably, our 
quantitative PCR results showed that RJ/eRJ regulated DAF-16 activity by affecting 
expressions of its target genes: sod-3, mtl-1, C32H11.4, and F21F3.3. Moreover, the 
elevated expressions of sod-3, mtl-1, F21F3.3, and repressed expression of C32H11.4 
indicated that RJ/eRJ might promote C. elegans stress resistance ability. 
The sod-3 gene, part of the SODs protein family that encodes an iron/manganese 
superoxide dismutase in mitochondrial, was found to be an anti-oxidant gene in C. 
elegans and conserved in mammals[171]. SODs are anti-oxidant enzymes that transfer 
superoxide radicals into hydrogen peroxide and oxygen. The mlt-1 gene encodes one of 
two C. elegans metalliothioneins and plays an important role in homeostasis and 
detoxification. It was discovered that the expression of intestinal mtl-1 gene was up-
regulated when worms were exposed to cadimium and heat shock[172]. It is possible that 
mtl-1 functions as an essential protector in oxidative stress, DNA damage, and heat shock 
stress. In addition to sod-3 and mtl-1, the expression of F21F3.3 was also up-regulated in 
RJ/eRJ treatment. Previous research revealed that F21F3.3 functions as a 
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methyltransferase to regulate protein folding and localization during the protein quality 
control process in the endoplasmic reticulum. Moreover, F21F3.3 was regulated by both 
DAF-16 and HCF-1 and may play a role in stress resistance[49]. C32H11.4 is one of a 
CUB-like protein, and its expression level was down-regulated in RJ/eRJ treated worms. 
Given that CUB-like proteins could affect the arsenate induced stress resistance and 
immune response[80], it is conceivable RJ/eRJ supplementation might strengthen worms’ 
immune system and protect them against certain stresses. Based on these quantitative 
PCR results, we speculated that RJ/eRJ might protect worms from stresses through 
regulating the expression of DAF-16 related stress resistant genes. In order to confirm our 
hypothesis, we did oxidative stress, UV irradiation, and heat shock stress assays to check 
whether RJ/eRJ has the anti-stress ability.  
First, we tested whether RJ/eRJ supplementation could protect C. elegans against 
oxidative stress. It is well known that oxidative stress is unavoidable and caused by the 
production of reactive oxygen species (ROS) from cellular mitochondrial respiration, 
which impairs a series of essential cellular components such as proteins, lipids, and DNA. 
In order to protect organisms from these damages, cells could produce superoxide 
dismutase (SOD), catalase, and glutathione peroxidases to transform the ROS to less 
toxic forms, which in turn detoxify the reactive intermediates and repair the cellular 
damages[165]. However, the balance of reactive oxygen production and consumption can 
be destroyed under certain conditions, such as persisting exogenous stress or in aging 
cells. When cells themselves cannot remove or degrade ROS efficiently, the 
accumulation of cellular damages will cause disease and accelerate the process of aging. 
82 
 
In our research, paraquat was used to mimic the oxidative stress conditions by 
producing a large amount of superoxide. Worms were treated with or without RJ/eRJ for 
two generations before being exposed to paraquat. Survival rates were observed to 
compare the differences in each treatment. Our results showed that both RJ and eRJ could 
protect C. elegans from paraquat induced oxidative stress and that there was no 
difference between RJ and eRJ’s anti-oxidant ability (Figure 4.1). Moreover, further 
results showed that DAF-16, SIR-2.1, HCF-1, and 14-3-3 were required in this anti-
oxidant response (Table 5). Noticeably, the p value of RJ/eRJ treatment versus that of the 
control group in daf-16 (mgDf50) and hcf-1 (ok599) mutants were just beyond the 
statistical significance (p<0.05) but very close to it. However, it is worth noting that in 
N2 worms’ oxidative stress experiment, the mean lifespan of RJ/eRJ treated worms were 
7 days and 6 days respectively when compared with the mean lifespan of control (4 days) 
(Figure 4.1). This result demonstrated that RJ/eRJ supplementation increased survival of 
N2 worms under paraquat induced oxidative stress by 50%. Although the p value of 
RJ/eRJ treated daf-16 (mgDf50) and hcf-1 (ok599) versus non-supplemented genetically 
matched mutants was close to 0.05, RJ/eRJ only increased survival of daf-16 (mgDf50) 
mutants by 10.65% and survival of hcf-1 (ok599) mutants by 16.30% (Table 5). These 
data suggested that DAF-16 and HCF-1 also played a very important role in RJ/eRJ 
mediated oxidative response, and other regulators might also be required in this 
beneficial effect.  
Accumulated evidence demonstrated that in addition to DAF-16, SKN-1, BAR-1, 
and SMK-1 were also important regulators in oxidative stress resistance[173, 174]. 
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Similar to DAF-16, SKN-1 is also a transcriptional factor downstream of IIS pathway, 
that has elevated expression in intestinal nuclei under stress or reduced IIS signaling. 
Additionally, SKN-1 modulates a set of downstream genes, which contribute to 
detoxification, cellular repair, and pathogen resistance[40]. SKN-1 is also regulated by 
P38 MAPK pathway to modulate oxidative stress tolerance[175]. Our results showed that 
RJ/eRJ supplementation altered the expression of C32H11.4, and it is well known that 
C32H11.4 is regulated by both DAF-16 and SKN-1 under stresses. SKN-1 may be 
involved in RJ/eRJ mediated anti-oxidative stress response. Another possible factor is β-
catenin BAR-1, a DAF-16/FOXO co-factor, which can directly bind to FOXO to enhance 
its transcriptional activity in mammals. Essers and colleagues published that the interplay 
between BAR-1 and FOXOs was increased under oxidative stress[173]. Moreover, BAR-
1 was required for the expression DAF-16 target gene sod-3 in response to oxidative 
stress. Our results showed that RJ/eRJ increased the gene expression of sod-3 
approximately two fold, which raised the possibility that BAR-1 might be required in 
RJ/eRJ mediated anti-oxidative response. Additionally, SMK-1, another essential 
regulator of DAF-16, could also influence DAF-16 associated anti-aging effects by 
modulating DAF-16 transcriptional activity. Dillin’s lab reported that SMK-1 was 
involved in several DAF-16 associated functions, such as UV irradiation, innate 
immunity, and oxidative stress response[47]. Further experiments are needed to 
investigate whether SKN-1, BAR-1, and SMK-1 are required in RJ/eRJ dependent anti-
oxidant response; this information would greatly advance our understanding of the 
mechanistic details of oxidative stress. 
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In addition to IIS pathway and DAF-16, the well-studied but controversial sirtuin 
pathway was also required in RJ/eRJ mediated anti-oxidative stress (Table 5). To date, 
cumulative publications claim that SIR-2.1/SIRT1 plays a key role in the anti-oxidant 
response, but the precise role of SIR-2.1/SIRT1 is still unclear[176]. Sirtuin enzymes are 
a conserved family of nicotinamide adenine dinucleotide (NAD)-dependent deacetylases 
and ADP-ribosyl-transferases, which regulate lifespan extension and stress resistance 
under dietary restriction. In a study of mammals, SIRT1 was shown to deacetylate and 
activate FOXOs (FOXO1, FOXO3a, and FOXO4) and promote the production of DNA 
repair factor[177]. Moreover, under modification of ROS, SIRT1 could activate P53 to 
reduce cellular apoptosis and promote peroxisome proliferator activated receptor gamma 
coactivator 1 α (PGC-1 α) to produce mitochondrial antioxidant enzyme manganese 
superoxide dismutase (MnSOD) in response to oxidative stress[178]. However, there are 
numerous contradictory results in sirtuin research, and the precise role of SIRT1 
mediated oxidative resistance is still elusive. Our study revealed that SIR-2.1 was 
required in RJ/eRJ mediated anti-oxidant response; therefore RJ/eRJ treatment could be 
utilized as a model to further investigate the detailed molecular mechanism of SIR-2.1 
regulation in response to oxidative stress.  
Paraquat, a common herbicide, not only induces an oxidative stress but also 
causes toxic effect to animals[179]. In our oxidative stress assay, worms’ mean lifespan 
was decreased from 12 days to 4 days because of the toxicity induced by the paraquat 
treatment (Figure 4.1). This result demonstrated that paraquat significantly shortened C. 
elegans lifespan because of its toxicity. Similarly, paraquat is also harmful to humans. In 
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2011, a U.S. National Institutes of Health study reported that farm workers were at a high 
risk for Parkinson’s disease because of their frequent usage of paraquat[180]. 
Furthermore, other studies revealed that the accumulation of oxidizing species caused by 
paraquat exposure could destroy cell structure and protein function, leading to the 
development of Parkinson’s disease in humans[181]. In addition to Parkinson’s disease, 
oxidative stress could also increase the risk of other age-related diseases such as cancer, 
Alzheimer’s disease, atherosclerosis, heart failure, and chronic fatigue syndrome[182].  
Collectively, our results indicated that RJ/eRJ not only protected worms from 
oxidative stress, but also alleviated paraquat induced toxicity. It is possible that RJ/eRJ 
might protect C. elegans against cytotoxicity and we will discuss this beneficial effect in 
the next chapter. 
It is well known that ROS is a major inducer of oxidative stress, but recent studies 
reported that ROS are not always harmful. Hamanaka and Chandel demonstrated that 
ROS also participates in cell signaling to regulate a variety of biological processes[165]. 
Moreover, several pathways could be activated by a short term of mild oxidative stress, 
which is beneficial for the immune system to kill pathogens and in turn lead a healthy 
aging. In 2008, Gems and Partridge published a theory of “mitohormesis,” which 
demonstrated that a low dose of stress could stimulate immunity to fight against 
pathogens and harmful effects to slow down the aging process[183]. It is possible that 
RJ/eRJ treatment might mimic the mild stress to strengthen the immune system and 
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DAF-16 transcriptional activity of C. elegans to promote lifespan extension and oxidative 
stress resistance. 
Next, we investigated whether RJ/eRJ could protect worms from DNA damage to 
maintain genome integrity. Based on our knowledge, cells maintain a good balance 
between ROS production and antioxidant defenses in normal conditions; however, 
dysregulation in this maintenance could cause mutations and cell death by high level 
accumulative oxidant damages to DNA[112]. In humans, a lot of environmental factors 
are known to induce DNA damages, such as solar UV irradiation, cigarette smoke, toxin, 
chemotherapeutics, and food contained chemicals. The unrepaired DNA damages could 
accelerate the aging process and increase the risk of cancers. In order to solve this 
problem, more and more scientists focus on investigating the molecular mechanisms of 
DNA damages and looking for effective treatment to prevent relative diseases[169].   
Given that reduced oxidative damages might be correlated with increased genome 
integrity, it is possible that RJ/eRJ might also help C. elegans in DNA damage response. 
In order to confirm this hypothesis, UV irradiation experiment was carried out to observe 
worms’ survival rate under RJ/eRJ supplementation and non-supplemented controls. In 
our study, UV irradiation was utilized to cause the formation of cyclobutane pyrimidine 
dimers (CPDs) and 6-4-photoproducts (6-4 PPs), which substantially distort double helix 
structure of DNA to induce DNA lesions in C. elegans.  
Our N2 worms’ UV stress assay showed that RJ/eRJ prolonged the survival of N2 
worms by 25% (RJ) and 50% (eRJ) under UV stress when compared with non-
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supplemented control worms (Figure 4.1). In order to investigate the molecular 
mechanism underlying this protective function, daf-16 (mgDf50), sir-2.1 (ok434), hcf-1 
(ok599), and 14-3-3 (n4426) mutant worms were exposed under UV irradiation with or 
without pre-treatment of RJ/eRJ for two generations. Surprisingly, our results showed 
that RJ/eRJ also increased the survival of hcf-1(ok599) mutants by 23.87% and the 
survival of 14-3-3(n4426) mutants by 22.41%, and the p value of RJ/eRJ versus control 
was less than 0.05. However, RJ/eRJ supplementation failed to increase the survival rate 
of daf-16 (MgDf50) and sir-2.1 (ok434) worms (Talbe 5), which demonstrated that only 
DAF-16 and SIR-2.1 were required in RJ/eRJ mediated UV stress resistance. 
RJ/eRJ supplementation might provide us a good model to investigate the 
molecular mechanism of DNA damage. A growing body of evidence indicated that there 
is a link between aging and age-related diseases to the loss of DNA repair capacity; the 
declined capacity of DNA repair resulted in accelerating the process of aging[114]. Our 
results showed that RJ/eRJ served as a beneficial supplementation to extend C. elegans 
lifespan as well as increase their resistance to UV stress, which correlates DNA repair 
capacity with healthy aging. Previous publications have revealed that the C. elegans 
mutant defective in IIS pathway lead a longer lifespan and higher DNA repair 
capacity[177], possibly because the reduced IIS elevated heat shock proteins (HSPs) 
expressions via increasing DAF-16 transcriptional activity. In the yeast model, it has been 
proposed that HSP90 could interplays with Ssl2, the yeast homolog of XPB, to promote 
enzymatic activities involved in repair of UV induced DNA lesions[184]. In a study of 
mammals, Mostoslavsky’s lab reported that SIRT6 plays an important role in DNA 
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damage repair and aging[185]. Although the detailed molecular basis of DNA repair 
capacity is unclear, accumulating evidence indicated that heat shock proteins, IIS 
pathway, and surtuin pathway might be involved in this process. 
In addition to IIS and surtuin pathways, other DNA repair pathways might be also 
involved in this RJ/eRJ mediated anti-DNA damage function. It is well known that cells 
are equipped with several DNA repair machineries to protect genome integrity against 
UV irradiation-induced cellular damage. The NER pathway, composed of numerous 
repair factors, is a general DNA repair machinery and displays multiple functions to 
repair many types of DNA damages, ranging from small base modification to double 
strand breaks[113]. Hyun and Ahn claimed that xpa-1, a nucleotide excision repair gene 
of C. elegans, was required in DNA repair response of IIS defective mutants[186]. This 
finding indicated that there are some interplays between IIS and NER pathways in DNA 
repair process. Moreover, it is reported that the mutations in human NER genes could 
cause several UV sensitive hereditary disorders, such as cockayne syndrome, premature 
aging, and neurodevelopmental problems, which underscored the relationship between 
DNA damage and aging.  
Our research provided a good model to investigate the molecular mechanism of 
DNA damage response. Further studies are needed to determine whether IIS/DAF-16 and 
SIR-2.1 interplay with DNA repair pathways in providing UV resistant benefits, which 
could help us to develop the effective treatment for DNA damage-associated disorders, 
such as cancer and premature aging[153].  
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The last stress response tested in our research was heat shock stress. Heat stress, 
also called thermal stress, is designed to treat organisms at a higher temperature than the 
ideal body temperature for a certain period. During heat stress, high temperature could 
cause damage to protein structure and function in some degree. In response to this stress, 
the cellular internal repair system is activated to up-regulate the expressions of heat shock 
proteins (HSPs) to repair or degrade the destructed proteins. As a master regulator to 
control the quality of proteins, HSPs function as molecular chaperones and play a critical 
role in protein folding and intracellular trafficking, additionally, and denatured proteins 
repair in stress and aging conditions[117]. 
Numerous studies have shown that some nutraceuticals have anti-heat stress 
functions. In a C. elegans model, it is reported that under thermal stress, the first larval 
stage (L1) or early L2 stage worms were induced to enter a dauer stage, which showed 
long lived phenotype and survival under harsh conditions. However, for the well-
developed young adult worms, heat shock stress could shorten their lifespan and cause 
reproductive problems. Numerous studies demonstrated that several antioxidant 
compounds could alleviate this heat shock induced protein damage. For example, α-lipoic 
acid and trolox, which were discovered as functional supplementation to increase C. 
elegans lifespan and heat shock resistance. In our previous study, our results showed that 
RJ/eRJ supplementation strengthened worms’ oxidative stress tolerance; thus it is highly 
possible that RJ/eRJ may also have thermal stress resistance. 
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In our study, wild type worms were pre-treated with RJ/eRJ for two generations 
under 25°C. Then the synchronized young adult worms were heat shocked at 35°C for 
three hours and returned back to 25°C to observe the survival of the worms receiving 
different treatments. Our results showed that heat shock shortened the mean lifespan of 
non-treated N2 worms from 12.97 days to 1.5 days. However, RJ/eRJ could increase 
worms’ survival rate nearly 6 fold (RJ) and 3 fold (eRJ) when compared with the survival 
rate of the controls (Figure 4.1). This result indicated that RJ/eRJ might protect C. 
elegans from heat shock stress, possibly because that some bioactive factors in RJ/eRJ 
could promote cells’ internal protein repair system to maintain protein structure and 
function in response to heat shock stress.  
Next, we compared the differences in thermal stress resistance in two types of 
Royal Jelly treated worms. Noticeably, although both RJ and eRJ could protect C. 
elegans from heat shock stress, the mean lifespan of heat shocked worms were 
significantly different in these two treatments: the mean lifespan of RJ treatment was 
around 9 days, whereas the eRJ treatment was only 4 days (Figure 4.1). This result 
indicated that RJ’s anti-thermal stress function was much better than that of eRJ. As we 
mentioned before in chapter three, the difference between RJ and eRJ was the enzyme 
pre-treatment, which removed some large proteins to reduce the immune response in eRJ 
powder. These removed large proteins might play an important role in heat shock 
resistance by stimulating the immune system. Overall, our data suggested that besides 
anti-oxidant and DNA repair capacity, RJ/eRJ also protected C. elegans from heat shock 
stress. 
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Next, we wondered whether DAF-16, SIR-2.1, HCF-1, and 14-3-3 are required in 
RJ/eRJ mediated heat shock resistance. Herein, daf-16 (mgDf50), sir-2.1 (ok434), hcf-1 
(ok599), and 14-3-3 (n4426) mutant worms were supplemented with or without RJ/eRJ 
for two generations before being treated with heat shock stress. The results showed that 
RJ/eRJ cannot prolong the survival of daf-16 (mgDf50), sir-2.1 (ok434), and 14-3-3 
(n4426) mutant worms under heat shock stress, which indicated that except for HCF-1, 
the other three proteins, DAF-16, SIR-2.1, and 14-3-3, were required in RJ/eRJ mediated 
heat shock resistance. Noticeably, the p value of RJ/eRJ treated hcf-1 (ok599) versus 
genetically matched controls was 0.046, less than the statistical significance. However, 
RJ/eRJ only increased the hcf-1 (ok599) mutants worms’ mean lifespan by 1.31 fold 
when compared with controls, which is far less than the increasing rate (6 fold in RJ and 
3 fold in eRJ) of mean lifespan elongation in heat shocked N2 worms (Table 5). This data 
indicated that HCF-1 was partially required in RJ/eRJ’s thermal stress resistance.  
Numerous papers published that DAF-16 could protect cells from various stresses 
by transcriptional up-regulation of its target stress response genes, especially heat shock 
proteins. Our quantitative PCR results showed that RJ/eRJ treatment increased the 
expression level of F21F3.3 (Figure 3.3), which functions in membrane proteins folding. 
Besides F21F3.3, DAF-16 also regulates a series of protein-turnover genes. The majority 
of these genes belong to heat shock protein (HSP) family, which modulate protein folding, 
trafficking, aggregation, and degradation to maintain proteostasis[144]. As an essential 
regulator to control protein quality, HSPs play a key role not only in normal conditions 
but also in stress environments and aging cells. During the cell growth, HSPs guide the 
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newly synthesized and misfolded proteins to fold into their correct and functional 
conformations, and the well folded proteins are shuttled to the right place by chaperones 
inside the cells. Moreover, the misfolded and unfolded proteins can be targeted by 
ubiquitin, a small group of HSPs, and proteases for degradation. In addition to this 
protein folding function, HSPs also served as a “cell monitor” to help the immune system 
detect the infected cells by presenting pieces of proteins or antigens on the cell 
surfaces[187]. Considering that our previous data showed that RJ/eRJ increased DAF-16 
transcriptional activity, it is highly possible that RJ/eRJ could also promote the gene 
expression levels of DAF-16 targeted heat shock proteins in heat shock resistance.  
As shown above, in addition to DAF-16, SIR-2.1 and 14-3-3 were also required in 
RJ/eRJ mediated heat shock tolerance; however, other factors, such as HSF-1, might also 
be involved in this anti-heat stress function. The Guarente lab proposed a model to 
explain the mechanism of heat shock stress: following the heat shock stress, SIR-2.1 can 
bind and activate DAF-16 in a 14-3-3 dependent manner[48]. It is conceivable that 
RJ/eRJ supplementation triggered the interplay of DAF-16, SIR-2.1, and 14-3-3 to 
activate DAF-16 downstream stress resistant genes, and thereby protected C. elegans 
from heat shock. However, it is worth noticing that in our mutant worms’ heat shock 
stress data, the p value of RJ/eRJ treated daf-16 (mgDf50) and sir-2.1 (ok434) versus their 
genetically matched control was 0.062 and 0.054 respectively, which indicated that 
besides DAF-16 and SIR-2.1, other factors might also be involved in this anti-heat shock 
resistance. It is highly possible that heat shock factor (HSF-1) is involved in this anti-
stress effect. As same as DAF-16, HSF-1 is also an important transcriptional factor 
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located at the downstream of IIS, and it is well known that DAF-16 and HSF-1 could act 
together to turn on a specific subset of genes to promote longevity[37]. Moreover, 
Morimoto’s lab claimed that SIRT1 deacetylated HSF-1 to up-regulate its target gene 
HSP70 expression in mammals study. As an important HSPs, HSP70 not only assist in 
the establishment of proper protein conformation, but also presents antigens and proteins 
across membranes to strengthen immune response, which is mainly regulated by HSF-
1[188]. Taken together, it is highly possible that HSF-1 might interplay with DAF-16 and 
SIR-2.1 to activate HSPs function in RJ/eRJ mediated heat shock stress resistance. Futher 
experiments are needed to test our hypothesis.  
It is well known that heat shock response is implicated in a series of conditions 
and diseases, such as neurodegenerative diseases, ischemic diseases, infection, and aging. 
Under stress conditions, proteins can be unfolded, misfolded, and aggregated[189]. 
Similarly, in the aging cells, the accumulated stresses and physiological decline 
associated with aging cause damages to cells by promoting protein aggregation to disrupt 
proteostasis[190]. In order to protect cells from this negative effect, cells themselves are 
equipped with an internal repair system, which could produce more HSPs to refold or 
degrade the destructed proteins and thereby assist the cell recovery in response to stresses. 
Overall, our studies revealed that RJ/eRJ supplementation protected C. elegans from heat 
shock stress, and this protection role reflected that RJ/eRJ posssessed capacity to assist C. 
elegans in the repair of protein damage. 
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In consideration that most neurodegenerative disorders are caused by protein 
misfolding, studying the molecular mechanism of heat shock stress could further help us 
to develop the therapeutic treatment of neurodegenerative diseases. RJ/eRJ 
supplementation provided us with more opportunities to further investigate the detailed 
molecular mechanism of heat shock resistance and age-related disorders. Additional 
studies are needed to further understand the relationship between stress resistance and 
pro-longevity. 
In summary, our results demonstrated that RJ/eRJ can protect C. elegans from a 
variety of stressors, such as oxidative stress, UV irradiation and heat shock stress. At 
least in part, these beneficial effects might act through modulating the interplays of DAF-
16, SIR-2.1, HCF-1, and 14-3-3. Moreover, our quantitative PCR results showed that 
RJ/eRJ induced the overexpression of several stress resistant genes under normal 
conditions, which indicated that RJ/eRJ’s stress resistance capacity might be dependent 
on its hermetic effects. It is conceivable that RJ/eRJ functions as a mild stress inducer to 
ameliorate stress and promote longevity. 
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CHAPTER FIVE : THE EFFECT OF ROYAL JELLY ON ALZHEIMER’S 
DISEASE 
5.1 Introduction: 
Aging is the greatest cause of neurodegenerative diseases, and a sizable aging 
population is already a major challenge for the healthcare system in American society. 
The statistical data estimated that more than 20% of the population will be over 65 years 
old by 2030, and the healthcare cost will reach $1.1 trillion by 2050[136].  
Alzheimer’s disease (AD) is the best known and the most studied neurological 
disorder in the aging population. AD is characterized by impairment of thinking, 
communication, and memory[127]. Two obvious phenotypes of AD patients are brain 
atrophy and neuropathological lesions, which exacerbate over time to interfere with daily 
activities. Numerous studies demonstrated that in all AD patients the depositions of 
neurofibrillary tangles (NFT) and extracellular amyloid plaques might disintegrate the 
neuron’s signaling transduction systems and thereby induce neural cell death as well as 
cognitive impairment[135].  
A growing body of studies has been published to elucidate the molecular 
mechanism of AD. Although the detailed molecular mechanism underlying AD is still 
unclear, AD is often considered as a “protein misfolding disease”, because it is caused by 
Aβ peptide aggregation and accumulation outside or inside of the neuronal cells[191]. It 
is well known that free radicals are generated by cell metabolism and stressors during cell 
growth, which cause damaging effects to the integrity of the proteome, leading to protein 
misfolding, aggregation, and amyloid formation. In order to combat this negative effect, 
96 
 
cells are equipped with protective machinery comprising a series of heat shock proteins 
(HSPs) that refold or degrade the misfolded and unfolded proteins and thus maintain a 
functional proteostasis. Unfortunately, the persisting harsh stresses and aging conditions 
overwhelm this protective mechanism, leading to aberrant proteins aggregation and 
cellular toxicity. It has been proposed that the aggregation and accumulation of these 
aberrant proteins are common features of many neurodegenerative diseases[131].  
AD, one of the costliest chronic diseases to society, has no efficient treatment; 
thus there is an urgent need for scientists to investigate the pathologic mechanism of AD 
and explore efficient therapeutic treatments to delay the progress of age-related disorders. 
Because nearly 80% of genes and pathways related to human diseases are present and 
conserved in C. elegans, it is believed that C. elegans is a good model to study the human 
diseases and evaluate the efficiency of novel drugs and treatments. Specifically, the C. 
elegans CL-2006 worm strain is reported as a classic AD model in many publications. 
CL-2006 worms transgenically express human Aβ3-42 peptides in body wall muscle and 
neuron cells. During the aging process, the aggregation and accumulation of Aβ species 
in muscle cells result in a progressive or rapid paralysis phenotype, which can be used as 
a direct indicator of Aβ toxicity[192].  
To date, numerous findings have shown that C. elegans AD model provided an 
excellent platform to investigate the beneficial anti-AD effects of nutraceuticals as well 
as molecular mechanisms of AD[22]. For instance, recent studies using the C. elegans 
model showed that curcumin, a phenol extracted from turmeric, could slow down the 
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development of Alzheimer’s disease and Parkinson disease by alleviating the 
proteotoxicity[193]. Guo et al reported that cranberry could protect worms against Aβ 
toxicity in AD; IIS/HSF-1 was required in this beneficial effect[123]. Moreover, LWDH 
(Liu Wei Di Huang), a traditional Chinese medicine, was discovered to delay AD 
development by increasing the level of heat shock proteins (HSPs) in C. elegans AD 
model[194]. Collectively, these studies show that dietary intervention provides a feasible 
and efficient method to combat age-related disorders through the IIS pathway.  
Our research focused on investigating the anti-aging effects of Royal Jelly. As a 
functional nutraceutical product, Royal Jelly (RJ) and its derived products have 
antimicrobial, anti-inflammation, immune-modulation, and anti-oxidation effects. The RJ, 
a bee product, is secreted by worker bees and used for developing and maintaining the 
queen bees.  Enzyme treated RJ (eRJ) is produced by digestion of RJ with a hydrolytic 
enzyme to decrease the allergenic properties of RJ[103]. In chapter four, our studies 
demonstrated that RJ/eRJ extended C. elegans lifespan and protected them against 
several stressors. Additionally, our genetic analysis showed that these beneficial effects 
required IIS pathway and DAF-16, which has been reported to play a key role in 
attenuating Aβ toxicity in C. elegans. To this end, it is highly possible that RJ/eRJ might 
have a protective effect to slow down the development of AD in C. elegans model.  
Herein, AD model CL-2006 worms were supplemented with RJ/eRJ to test this 
hypothesis. Strikingly, our results showed that RJ/eRJ significantly slowed down the 
progression of Aβ toxicity induced paralysis by reducing the Aβ species. Afterwards, the 
98 
 
genetic analysis showed that this beneficial effect was dependent on IIS/DAF-16, rather 
than HSF-1 and SKN-1. Our results consistently demonstrated that RJ/eRJ increased the 
protein solubility to maintain a healthy proteostasis in aged worms. Given that AD is a 
protein misfolding disease and caused by proteotoxicity, our western blot results showed 
that RJ/eRJ could alleviate the cytotoxicity in AD worms by increasing the solubility of 
Aβ species, which indicated that RJ/eRJ might influence the conformation of Aβ species 
and thus slow down the development of AD.  
Taken together, our findings not only implied the molecular mechanism of RJ/eRJ 
mediated protection against Aβ toxicity but also shed light on the relationship between 
proteostasis and neurodegenerative disorders. 
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5.2 Results: 
5.2.1 RJ/eRJ supplementation prolongs the lifespan of AD model C. elegans 
It has previously been showed that RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, 
respectively) significantly increased the lifespan of wild type C. elegans, herein we want 
to test whether RJ/eRJ also has the same beneficial effect on trans-genetic AD worms. 
CL-2006 strain, engineered transgenic worms which express human Aβ proteins in body 
muscles and neurons, were treated with our without RJ/eRJ from young adult stage, and 
their lifespan were measured at 20°C. In consistent with our previous study, our data 
showed that RJ/eRJ significantly increased the lifespan of CL-2006 worms. Comparing 
with non-supplemented control, the mean lifespan of RJ/eRJ treated CL-2006 worms 
averagely increased from 14.780 days to 17.000 days (RJ) and 17.188days (eRJ), 
resulting in an increase of 15.02% and 16.29%, respectively (Figure 5.1 and Table 6). 
Because of numerous studies revealed that lifespan extension is often associated with 
increased stress resistance and anti-age related disorders function, this finding implied 
that RJ/eRJ supplementation might be effective to AD treatment. 
5.2.2 RJ/eRJ delays the progression of paralysis in AD worms by reducing the 
amount of Aβ species 
Paralysis is a major marker to directly reflect Aβ toxicity in AD worms. Briefly, 
we investigated whether RJ/eRJ could slow down the progression of AD worms’ 
paralysis. Meanwhile, the amount of Aβ species was tested to determine whether RJ/eRJ 
could influence Aβ production to affect Aβ-induced paralysis in AD worms. 
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5.2.2.1 RJ/eRJ supplementation delays the progression of Aβ toxicity induced 
paralysis in AD worms 
Synchronized CL-2006 young adult worms were treated with or without RJ/eRJ 
(2mg/mL RJ and 1mg/mL eRJ respectively) supplementation at 20°C and paralysis were 
measured every day until all worms were paralyzed. Our data indicated that RJ/eRJ 
supplementation dramatically delayed the progression of CL-2006 worms’ paralysis 
when compared with the non-supplemented controls (Figure 5.2). Specifically, RJ/eRJ 
extended the mean time of paralysis from 10.901 days to 12.656 days and 12.091 days, 
displaying an average increase of mean paralysis time by16.10% and 10.92% when 
compared with control group, respectively (Table 7). In considering that paralysis is a 
direct indicator of Aβ toxicity, our finding suggested that in addition to lifespan extension, 
RJ/eRJ also alleviated Aβ toxicity in AD model worms. 
5.2.2.2 RJ/eRJ supplementation reduces Aβ species amount in AD worms 
Given that AD worms’ paralysis is caused by Aβ toxicity, numerous studies 
reported that many nutraceuticals possessed the ability to slow down the AD 
development by mitigating Aβ toxicity through decreasing Aβ species. We questioned 
whether RJ/eRJ followed the same rule to delay the development of AD. In order to 
address this concern, synchronized CL-2006 young adult worms were treated with or 
without RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, respectively) for 10 days at 20°C. 
Afterwards, 10-day aged worms were collected to conduct a dot blot assay to test whether 
RJ/eRJ supplementation influenced the amount of Aβ species. Image-J software was used 
to analyze the data. Our dot blot assay result showed that RJ/eRJ displayed a decrease of 
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Aβ species amount by 13.61% and 21.90% comparing with non-supplemented controls, 
which was statistically significant (p<0.05) (Figure 5.2). Taken together, given the 
progression of CL-2006 worms’ paralysis is driven by Aβ toxicity and the amount of Aβ 
species contributes to Aβ toxicity, out finding demonstrated that RJ/eRJ attenuated Aβ 
toxicity by reducing the level of Aβ species amount.  
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Figure 5.1 RJ and eRJ extend the lifespan of transgenic C. elegans expression 
Aβ peptides.  (A). Wild type N2 worms were supplemented with RJ/eRJ (2mg/mL RJ 
and 1mg/mL eRJ, respectively). (B). CL-2006 worms, transgenic C. elegans 
constitutively expressing Aβ, were treated with RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, 
respectively). Each lifespan experiment was repeated at least three independent times 
with similar results. Quantitative data and statistical analyses for the representative 
experiments were included in Table 6. 
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Figure 5.2 RJ/eRJ treatment mitigates Aβ toxicity in C. elegans by reducing Aβ 
species amount. (A). CL-2006 worms were treated with RJ/eRJ (2mg/mL RJ and 
1mg/mL eRJ, respectively) to carry out paralysis assays. The RJ/eRJ treated CL-
2006 worms (dashed line) showed delayed progression of body paralysis as 
compared to control worms (solid line). Each paralysis assay was conducted in 
triplicates and repeated at least three times with similar results. “% paralysis” 
indicated the average paralysis among the multi-replicates and error bars represent 
the standard deviation. (B). Dot blot analysis was carried out to measure the total 
amount of Aβ species using 10-day old CL-2006 worms. Total Aβ species were 
quantified by Image-J software.  A dramatic reduction of total Aβ species were 
observed in RJ/eRJ treated CL-2006 worms.  The graph showed the mean intensity 
of Aβ species and was the result of three independent experiments. The p value was 
calculated by using Student’s t-test. “*” indicated p<0.05 when comparing to 
controls.   
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Table 6. The lifespan Data of N2 and CL-2006 worms at 20°C 
strain     Mean±SE Median No. of Worms p value 
N2*     14.892±0.401 15.00 84   
N2 + 2mg/mL RJ* 
 
17.848±0.401 18.00 86 0.002 
N2 + 1mg/mL eRJ* 
 
18.221±0.438 19.00 88 0.001 
CL-2006 ** 
  
14.780±0.361 15.00 97 
 CL-2006 + 2mg/mL RJ** 
 
17.000±0.406 18.00 97 0.001 
CL-2006 + 1mg/mL 
eRJ**   17.188±0.312 17.00 105 0.001 
 
Note: Lifespan and standard error are shown in days. The lifespan experiments were 
repeated at least three times with similar results, and the data for representative 
experiments are shown. The lifespan data were analyzed using the log-rank test and p 
values for each individual experiment are shown. 
*Results presented in Figure 5.1 A      **Results presented in Figure 5.1 B 
 
Table 7. The Paralysis Data of CL-2006 Worms at 20°C 
strain     Mean±SE Median No. of Worms p value 
CL-2006
†
 
  
10.901±0.143 11.00 394 
 CL-2006 + 2mg/mL RJ
†
 
 
12.656±0.149 12.00 449 0.001 
CL-2006 + 1mg/mL eRJ
†
   12.091±0.196 13.00 389 0.001 
 
Notes: Paralysis and standard error were shown in days. The paralysis experiments were 
repeated at least three times with similar results, and the data for representative 
experiments were shown. The paralysis data were analyzed using the log-rank test and p 
values for each individual experiment are shown. 
†Results presented in Figure 5.2 A.  
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5.2.3 RJ/eRJ requires IIS/DAF-16, rather than HSF-1, SKN-1, and JNK-1, to delay 
the development of body paralysis in C. elegans 
Moll demonstrated that reduction of IIS prevented neurodegenerative diseases in 
mammals and worms by increasing the transactivities of its transcriptional factors: DAF-
16, HSF-1, and SKN-1[143]. Moreover, it has been proposed that, in parallel to IIS, JNK 
pathway also plays an important role in Alzheimer’s disease and regulate the activities of 
these IIS pathway downstream transcriptional factors (DAF-16, SKN-1, and HSF-1). 
Thus we wondered whether RJ/eRJ requires IIS pathway and JNK pathway to slow down 
the development of AD in C. elegans. 
5.2.3.1 Insulin Signaling Pathway and DAF-16 are required in RJ/eRJ mediated 
protection from Aβ toxicity 
In chapter three, our genetic analysis showed that IIS/DAF-16 was involved in 
RJ/eRJ mediated lifespan extension. Considering the potential link between pro-longevity 
and anti-AD function, we questioned whether IIS/DAF-16 also plays a key role in RJ/eRJ 
mediated protection against Aβ toxicity. In order to address this concern, genetic epistasis 
assays were carried out in CL-2006 worms treated with and without RJ/eRJ 
supplementation to monitor their progression of paralysis.  
Briefly, RNA interference (RNAi) was utilized to distinctively knock down the 
gene expression of major IIS pathway components (daf-2 and age-1 respectively) and an 
important IIS pathway downstream transcriptional factor (daf-16). CL-2006 worms were 
synchronized on NGM plates seeded with particular RNAi or a paired RNAi control 
(L4440 empty vector for age-1 RNAi and daf-16 RNAi, PAD-12 empty vector for daf-2 
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RNAi) bacteria. Afterwards, the synchronized young adult worms treated with or without 
RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, respectively) were fed with particular RNAi 
bacteria to carry out paralysis assays. Worms’ paralysis was observed every day until all 
worms were paralyzed. Meanwhile, another set of young adult worms supplemented with 
or without RJ/eRJ were fed with particular RNAi (daf-16, age-1, and daf-2, respectively) 
and paired RNAi control bacteria for 6 days. Then the 6-day aged worms of different 
treatments were collected to conduct a quantitative PCR experiment to check the RNAi 
efficiency.  
In our paralysis assay results, CL2006 worms fed with two RNAi paired control 
bacteria were set up as system controls. When compare with non-treated controls, RJ/eRJ 
supplementation dramatically delayed the progression of paralysis in CL-2006 worms fed 
with two RNAi paired control bacteria, which confirmed that our experimental system 
and RJ/eRJ treatment method worked well. Then we analyzed the paralysis assay data in 
each RNAi (dat-16, age-1, and daf-2 respectively) bacteria fed worms. Interestingly, our 
data showed that the beneficial effects of RJ/eRJ on delaying the progression of paralysis 
was completely withdrew in CL-2006 worms fed with age-1 RNAi, daf-2 RNAi and daf-
16 RNAi bacteria comparing with RNAi matched non-supplemented controls, 
respectively (Figure 5.3 A, B, and C). Moreover, the quantitative PCR results showed 
that the RNAi successfully inhibited almost 80-90% gene expressions (age-1, daf-2, and 
daf-16), respectively (Figure 5.3 D). This result indicated that RNAi method worked 
efficiently to repress selected gene expression in genetic epistasis assays, and further 
confirmed that our genetic epistasis assay results were reliable. Summarily, our findings 
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showed that IIS and DAF-16 were required not only in RJ/eRJ mediated pro-longevity 
effect but also in protection against Aβ toxicity.  
In chapter three, we reported that RJ/eRJ extended C. elegans lifespan through 
regulating the trans-activity of DAF-16. In consideration of DAF-16 was also involved in 
RJ/eRJ mediated protection of Aβ toxicity, we questioned whether this beneficial effect 
also acts through activating the DAF-16 target genes. To this end, synchronized CL-2006 
young adult worms were treated with or without RJ/eRJ for 6 days, and several 
representative DAF-16 target genes were selected to measure their expression levels in 
each treatment. Our results showed that sod-3, mtl-1, Y71H2Ar.2, hsp-16.2, and hsp-12.6 
were up-regulated in CL-2006 worms treated with RJ/eRJ when compared with non-
supplemented controls (Figure 5.4). This finding indicated that RJ/eRJ mediated 
protection against Aβ toxicity might be dependent on elevating the transactivity of DAF-
16.  
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Figure 5.3 RJ/eRJ requires IIS/DAF-16 to protect against Aβ toxicity in CL-
2006 worms.  (A). RJ/eRJ cannot slow down the progression of body paralysis in CL-
2006 worms with reduced IIS by daf-2 RNAi. (B). RJ/eRJ cannot delay the progression 
of Aβ toxicity-induced paralysis in CL-2006 worms with reduced IIS by age-1 RNAi. (C). 
RJ/eRJ cannot delay the progression of Aβ toxicity-induced paralysis in CL-2006 worms 
with reduced DAF-16 level by daf-16 RNAi. Each paralysis assay was repeated at least 
three independent times with similar results. “% paralysis” indicated the average 
paralysis among the multi-replicates and error bars represent the standard deviation. (D). 
RNA interference efficiently knocked down selected gene expression (age-1, daf-2, and 
daf-16 respectively) in CL-2006 worms’ genetic epistasis assays. The expression levels 
of age-1, daf-2, and daf-16 were measured with qRT-PCR in CL-2006 worms 
supplemented with RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, respectively). CL-2006 worms 
feeding with paired RNAi control (L4440 empty vector for age-1 and daf-16, PAD-12 
empty vector for daf-2) severed as controls to check gene knock down efficiency.  The 
data from three independent experiments were pooled to calculate the mean mRNA level 
normalized to the internal control act-1. The standard errors of the mean (SEM) were 
shown. “*” indicated p<0.05 when compared to paired RNAi bacteria controls. 
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Figure 5.4 The transcript levels of mtl-1, sod-3, Y71H2AR.2, hsp-12.6, and hsp-
16.2 are up-regulated through RJ/eRJ mediated elevation of DAF-16’s trans-
activity.  The expression levels of aip-1, F10D7.5, mtl-1, sip-1, sod-3, Y71H2AR.2, hsp-
12.6, hsp-16.2, hsp-70, and T02G5.10 were measure with qRT-PCR in CL-2006 worms 
supplemented with RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, respectively). The data from 
three independent experiments were pooled to calculate the mean mRNA level 
normalized to the internal control act-1. The standard errors of the mean (SEM) were 
shown. “*” indicated p<0.05 when compared to non-treated controls. 
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Table 8. The Paralysis Data of Worms at 20°C 
strain   Mean±SE Median No. of Worms p value 
EV(L4440) RNAi
†,ⱡ
 
 
10.708±0.188 11.00 
 
253 
  EV(L4440) RNAi+RJ
†,ⱡ
 
 
13.008±0.234 13.00 
 
261 
 
5.68E-05 
EV(L4440) RNAi+eRJ
†,ⱡ
 
 
12.379±0.223 12.00 
 
256 
 
1.41E-04 
age-1 RNAi
†
 
 
15.391±0.201 15.00 
 
335 
  age-1 RNAi+RJ
†
 
 
15.463±0.201 15.00 
 
348 
 
0.222 
age-1 RNAi+eRJ
†
 
 
15.438±0.214 15.00 
 
331 
 
0.095 
daf-16 RNAi
ⱡ
 
 
8.821±0.113 9.00 
 
340 
  daf-16 RNAi+RJ
ⱡ
 
 
9.053±0.115 9.00 
 
318 
 
0.53 
daf-16 RNAi+eRJ
ⱡ
 
 
8.909±0.128 9.00 
 
339 
 
0.47 
EV(PAD12) RNAi* 
 
12.734±0.181 13.00 
 
323 
  EV(PAD12) RNAi+RJ* 
 
15.699±0.205 16.00 
 
316 
 
1.31E-04 
EV(PAD12) RNAi+eRJ* 
 
15.006±0.194 15.00 
 
315 
 
5.81E-05 
daf-2 RNAi* 
 
19.253±0.273 20.00 
 
348 
  daf-2 RNAi+RJ* 
 
19.389±0.313 20.00 
 
314 
 
0.712 
daf-2 RNAi+eRJ*   19.296±0.305 21.00   301   0.728 
 
Notes: Paralysis and standard error are shown in days. The paralysis experiments were 
repeated at least three times with similar results, and the data for representative 
experiments were shown. The paralysis data were analyzed using the log-rank test and p 
values for each individual experiment are shown. 
†Results presented in Figure 5.3 A         
*Results presented in Figure 5.3 B 
ⱡ Results presented in Figure 5.3 C 
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5.2.3.2 HSF-1 and SKN-1, two other important transcriptional factors in IIS 
pathway are dispensable in RJ/eRJ mediated protection against Aβ toxicity 
Besides of DAF-16, SKN-1 and HSF-1 are another two important transcriptional 
factors at the downstream of IIS pathway, and also play a key role in regulating Aβ 
aggregation to alleviate Aβ toxicity in C. elegans. To this end, we examined whether 
SKN-1 and HSF-1 were required in this RJ/eRJ mediated beneficial effect. CL-2006 
worms supplemented with or without RJ/eRJ were fed with RNAi bacteria of skn-1 and 
hsf-1, respectively. CL-2006 worms fed with RNAi control (L4440 empty vector) 
bacteria served as a system control. Meanwhile, another set of young adult worms treated 
with or without RJ/eRJ were fed with particular RNAi (skn-1 and hsf-1 respectively) and 
paired RNAi control bacteria for 6 days. Then the 6-day old worms in each treatment 
were collected to carry out a quantitative PCR experiment to check the efficiency of each 
RNAi. 
Our results showed that RJ/eRJ still delayed the progression of paralysis in CL-
2006 worms fed with skn-1 and hsf-1 RNAi bacteria respectively, comparing with 
matched non-supplemented controls (Figure 5.5 A and B). Based on the analysis, RJ/eRJ 
treated worms displayed an average increase of the mean paralysis time by of 24.67% (RJ) 
and 22.18% (eRJ) when fed with hsf-1 RNAi bacteria. Similarly, RJ/eRJ supplemented 
worms showed an average increase of mean paralysis time by 17.74% (RJ) and 16.56% 
(eRJ) when fed with skn-1 RNAi bacteria, which were spastically significant when 
comparing with non-treated control group (Table 9). Considering that in paired RNAi 
control bacteria group, RJ/eRJ supplementation delayed 21.48% (RJ) and 15.61% (eRJ) 
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of mean paralysis time when compared with non-supplemented controls, which were 
nearly the same in hsf-1 and skn-1 RNAi bacteria fed worms. This comparison indicated 
that SKN-1 and HSF-1 might be not dispensable in RJ/eRJ mediated protection against 
Aβ toxicity. Moreover, RNAi efficiency was needed to be checked before we further 
confirmed the genetic data. Our quantitative PCR results showed that the RNA 
interference applied in this experiment successfully repressed almost 50% of skn-1 gene 
expression and 90% of hsf-1 gene expression, which indicated that RNAi method worked 
successfully to knock down selected gene expression in genetic epistasis assays and our 
genetic results were reliable. Taken together, our findings suggested that SKN-1 and 
HSF-1 were not required in RJ/eRJ mediated protection against Aβ toxicity. 
5.2.3.3 JNK pathway is not required in RJ/eRJ mediated protection against Aβ 
toxicity in AD worms 
Our previous results showed that RJ/eRJ required IIS/DAF-16 to delay the 
progression of paralysis in AD worms. It is well known that in addition to IIS pathway, 
JNK pathway could also regulate the activity of DAF-16. Moreover, JNK pathway also 
plays a key role in the development of neurodegenerative diseases. Next, we tested 
whether jnk-1, a major component of JNK pathway, is required by RJ/eRJ in the 
protection of Aβ toxicity. Following the same method, CL-2006 worms treated with or 
without RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, respectively) were fed with jnk-1 RNAi 
and control RNAi (L4440 empty vector) bacteria to observe paralysis. Meanwhile, 
another set of worms treated with or without RJ/eRJ were fed with jnk-1 RNAi and 
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control RNAi for 6 days. Then the 6 day old worms in each treatment were collected to 
conduct a quantitative PCR experiment to check the efficiency of RNA interference.  
Our results showed that RJ/eRJ still slowed down the progression of paralysis of 
CL-2006 worms fed with jnk-1 RNAi bacteria (Figure 5.5 C). Specifically, RJ/eRJ 
increased the mean paralysis time by 22.43% (RJ) and 22.59% (eRJ) when compared 
with non-treated controls, and this increased rate was almost as same as RNAi control 
bacteria (Table 9). Moreover, the quantitative PCR result showed that jnk-1 RNAi 
applied in this experiment repressed almost 70% of jnk-1 gene expression, which 
confirmed that jnk-1 RNAi efficiently knocked down jnk-1 gene expression in genetic 
epistasis assays and our genetic results were reliable (Figure 5.5 D). Taken together, the 
results suggested that JNK pathway were not required in RJ/eRJ mediated protection 
against Aβ toxicity.  
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Figure 5.5 RJ/eRJ mediated protection against Aβ toxicity is dispensable on 
HSF-1, SKN-1 and JNK-1.  (A). RJ/eRJ slowed down the progression of body 
paralysis in CL-2006 worms with reduced HSF-1 level by hsf-1 RNAi. (B). RJ/eRJ 
delayed the progression of toxicity-induced paralysis in CL-2006 worms with decreased 
SKN-1 level by skn-1 RNAi. Each paralysis assay was repeated at least three independent 
times with similar results. “% paralysis” indicated the average paralysis among the multi-
replicates and error bars represent the standard deviation. (C). RJ/eRJ mediated 
protection against Aβ toxicity was dispensable on JNK pathway. RJ/eRJ slowed down the 
progression of body paralysis in CL-2006 worms with reduced JNK-1 level by jnk-1 
RNAi. Each paralysis assay was repeated at least three independent times with similar 
results. “% paralysis” indicated the average paralysis among the multi-replicates and 
error bars represent the standard deviation. (D). RNA interference efficiently knocked 
down the selected gene expression (hsf-1, skn-1, and jnk-1, respectively) in CL-2006 
worms’ genetic epistasis assays. The expression levels of hsf-1, skn-1, and jnk-1 were 
measured with qRT-PCR in CL-2006 worms supplemented with RJ/eRJ (2mg/mL RJ and 
1mg/mL eRJ, respectively). CL-2006 worms feeding with paired RNAi control (L4440 
empty vector) severed as controls to check gene knock down efficiency.  The data from 
three independent experiments were pooled to calculate the mean mRNA level 
normalized to the internal control act-1. The standard errors of the mean (SEM) are 
shown. “*” indicated p<0.05 when compared to paired RNAi bacteria controls. 
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Table 9. The Paralysis Data of CL-2006 Worms at 20°C 
strain     Mean±SE Median No. of Worms p value 
EV(L4440) RNAi
*,†,ⱡ
 
 
10.708±0.188 11.00 
 
253 
  EV(L4440) RNAi+RJ
*,†,ⱡ
 
 
13.008±0.234 13.00 
 
261 
 
5.68E-05 
EV(L4440) RNAi+eRJ
*,†,ⱡ
 12.379±0.223 12.00 
 
256 
 
1.41E-04 
jnk-1 RNAi* 
 
8.737±0.159 9.00 
 
308 
  jnk-1 RNAi+RJ* 
 
10.697±0.151 11.00 
 
304 
 
1.37E-04 
jnk-1 RNAi+eRJ* 
 
10.771±0.147 11.00 
 
328 
 
6.27E-05 
hsf-1 RNAi
†
 
 
9.401±0.187 10.00 
 
309 
  hsf-1 RNAi+RJ
†
 
 
11.720±0.166 12.00 
 
307 
 
2.65E-05 
hsf-1 RNAi+eRJ
†
 
 
11.486±0.157 12.00 
 
313 
 
2.65E-05 
skn-1 RNAi
ⱡ
 
 
10.435±0.167 11.00 
 
294 
  skn-1 RNAi+RJ
ⱡ
 
 
12.286±0.197 13.00 
 
311 
 
0.001 
skn-1 RNAi+eRJ
ⱡ
   12.163±0.183 13.00   301   0.001 
 
Notes: Paralysis and standard error are shown in days. The paralysis experiments were 
repeated at least three times with similar results, and the data for representative 
experiments were shown. The paralysis data were analyzed using the log-rank test and p 
values for each individual experiment are shown. 
*Results presented in Figure 5.5 C         
†Results presented in Figure 5.5 A         
ⱡResults presented in Figure 5.5 B 
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5.2.3.4 RJ/eRJ partially requires SIR-2.1, rather than HCF-1 and 14-3-3, to protect 
AD worms against Aβ toxicity 
In chapter three, we reported that SIR-2.1, HCF-1, and 14-3-3, three important 
DAF-16 co-factors, modulated DAF-16 activity to extend the lifespan of C. elegans. 
Considering that the link between pro-longevity and anti-AD functions, herein we 
wondered whether these three proteins were involved in RJ/eRJ mediated protection of 
Aβ toxicity. CL-2006 worms supplemented with or without RJ/eRJ were fed with RNAi 
control (L4440 empty vector) bacteria and particular RNAi bacteria of sir-2.1, hcf-1, and 
ftt-2, respectively. Meanwhile, another set of young adult worms treated with or without 
RJ/eRJ were fed with particular RNAi (sir-2.1, hcf-1, and ftt-2, respectively) and paired 
RNAi control bacteria for 6 days. Then the worms were collected to conduct a 
quantitative PCR experiment to determine the efficiency of RNAi. Based on the analysis, 
our results showed that RJ/eRJ still delayed the progression of paralysis in CL-2006 
worms fed with sir-2.1, hcf-1, and ftt-2 RNAi bacteria respectively, when compared with 
matched non-supplemented controls (Figure 5.6 A, B, and C). It is worth noticing that 
RJ/eRJ supplemented worms displayed an increase of mean paralysis time by 7.07% (RJ) 
and 7.03% (eRJ) when fed with sir-2.1 RNAi bacteria comparing with the non-treated 
controls fed with the same RNAi bacteria. However, in the paired RNAi control bacteria 
group, RJ/eRJ supplementation extended 21.48% (RJ) and 15.61% (eRJ) of mean 
paralysis time when compared with non-supplemented controls, which were nearly 2 to 3 
times longer than the increased rates in sir-2.1 RNAi bacteria group (Table 10). These 
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results demonstrated that SIR-2.1 was partially required in RJ/eRJ mediated protection of 
Aβ toxicity.  
Next, the same strategy was utilized to analyze whether another two proteins, 
HCF-1 and 14-3-3, are involved in this RJ/eRJ mediated beneficial effect. Specifically, 
RJ/eRJ supplemented CL-2006 worms showed an average increase of mean paralysis 
time by 20.19% (RJ) and 14.84% (eRJ) when fed with ftt-2 RNAi bacteria. Similarly, 
RJ/eRJ supplemented worms showed an average increase of mean paralysis time by 
13.31% (RJ) and 12.98% (eRJ) when fed with hcf-1 RNAi bacteria. Interestingly, unlike 
sir-2.1 RNAi treatment, these two genes RNAi paralysis assays showed the RJ/eRJ 
mediated mean paralysis extended rates were almost the same in worms fed with hcf-1 
RNAi and ftt-2 RNAi bacteria groups, when compared with worms fed with paired RNAi 
control bacteria (Figure 5.6 B and C). These data implied that HCF-1 and 14-3-3 were 
dispensable in RJ/eRJ mediated protection of Aβ toxicity. 
 In order to confirm our genetic data, a quantitative PCR experiment result was 
carried out to check the efficiency of RNAi. As we had expected, the RNAi applied in 
this experiment repressed almost 80% of sir-2.1 gene expression, 75% of ftt-2 gene 
expression, and 85% of hcf-1 gene expression (Figure 5.6 D). These results indicated that 
RNAi successfully knocked down the selected genes expression in paralysis assays and 
further confirmed that our genetic analysis data were reliable. Collectively, our results 
suggested that SIR-2.1 was partially required in RJ/eRJ mediated protection against Aβ 
toxicity, whereas HCF-1 and 14-3-3 were dispensable in this beneficial effect. 
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Figure 5.6 RJ/eRJ mediated protection against Aβ toxicity is dispensable on 
HCF-1 and 14-3-3, but partially dependent on SIR-2.1.  (A). RJ/eRJ slowed down 
the progression of body paralysis in CL-2006 worms with reduced SIR-2.1 level by sir-
2.1 RNAi. (B). RJ/eRJ delayed the progression of toxicity-induced paralysis in CL-2006 
worms with decreased HCF-1 level by hcf-1 RNAi. (C). RJ/eRJ delayed the progression 
of toxicity-induced paralysis in CL-2006 worms with decreased 14-3-3 level by ftt-2 
RNAi.  Each paralysis assay was repeated at least three independent times with similar 
results. “% paralysis” indicated the average paralysis among the multi-replicates and 
error bars represent the standard deviation. (D).RNA interference efficiently knocked 
down selected gene expression (sir-2.1, hcf-1, and ftt-2, respectively) in CL-2006 worms’ 
genetic epistasis assays. The expression levels of sir-2.1, hcf-1, and ftt-2 were measured 
with qRT-PCR in CL-2006 worms supplemented with RJ/eRJ (2mg/mL RJ and 1mg/mL 
eRJ, respectively). CL-2006 worms feeding with paired RNAi control (L4440 empty 
vector) severed as controls to check gene knock down efficiency.  The data from three 
independent experiments were pooled to calculate the mean RNA level normalized to the 
internal control act-1. The standard errors of the mean (SEM) were shown. “*” indicated 
p<0.05 when compared to paired RNAi bacteria controls. 
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Table 10. The Paralysis Data of CL-2006 Worms at 20°C 
strain     Mean±SE Median No. of Worms p value 
EV(L4440) RNAi* 
 
10.708±0.188 11.00 
 
253 
  EV(L4440) RNAi+RJ* 
 
13.008±0.234 13.00 
 
261 
 
5.68E-05 
EV(L4440) RNAi+eRJ* 
 
12.379±0.223 12.00 
 
256 
 
1.41E-04 
sir-2.1 RNAi* 
 
10.520±0.151 11.00 
 
277 
  sir-2.1 RNAi+RJ* 
 
11.264±0.172 12.00 
 
277 
 
0.002 
sir-2.1 RNAi+eRJ* 
 
11.260±0.166 12.00 
 
285 
 
0.002 
EV(L4440) RNAi
†,ⱡ
 
 
11.099±0.133 11.00 
 
332 
  EV(L4440) RNAi+RJ
†,ⱡ
 
 
12.848±0.179 13.00 
 
329 
 
7.51E-04 
EV(L4440) RNAi+eRJ
†,ⱡ
 
 
12.477±0.163 13.00 
 
329 
 
8.68E-04 
ftt-2 RNAi
†
 
  
10.381±0.147 10.00 
 
381 
  ftt-2 RNAi+RJ
†
 
 
12.477±0.186 12.00 
 
329 
 
3.13E-04 
ftt-2 RNAi+eRJ
†
 
 
11.922±0.160 12.00 
 
375 
 
4.28E-04 
hcf-1RNAi
ⱡ
 
  
13.005±0.121 13.00 
 
381 
  hcf-1 RNAi+RJ
ⱡ
 
 
14.736±0.146 15.00 
 
329 
 
0.002 
hcf-1 RNAi+eRJ
ⱡ
   14.693±0.133 15.00   375   0.002 
 
Notes: Paralysis and standard error were shown in days. The paralysis experiments were 
repeated at least three times with similar results, and the data for representative 
experiments are shown. The paralysis data were analyzed using the log-rank test and p 
values for each individual experiment are shown. 
*Results presented in Figure 5.6 A     
†Results presented in Figure 5.6 B         
ⱡResults presented in Figure 5.6 C 
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5.2.4 RJ/eRJ supplementation increases protein solubility in aged C. elegans 
Aging and persisting stresses cause cumulative damages to cells, which could 
destruct proteins’ conformation to induce the deposition of insoluble proteins. Some 
nutraceuticals could combat this damage by promoting the protein solubility to maintain a 
functional proteostasis. Considering that RJ/eRJ slowed down the progression of 
paralysis in AD worms, we wondered that whether RJ/eRJ’s beneficial effect is 
dependent on promoting solubility of proteins in aged worms. To this end, synchronized 
young adult N2 worms and CL-2006 worms were treated with or without RJ/eRJ for 10 
days. Then the aged worms were collected for total proteins extraction. After sonication 
and high speed centrifugation, soluble fraction was isolated from the total proteins. SDS-
PAGE and Image-J were utilized to investigate whether RJ/eRJ affect the solubility of 
proteins in aged C. elegans. Our results showed that RJ/eRJ increased 26.95% (RJ) and 
26.87% (eRJ) soluble protein amount relative to non-supplemented controls in N2 worms. 
Similarly, RJ/eRJ also displayed an average increase of CL-2006 worms’ soluble proteins 
amount by 27.13% (RJ) and 21.27% (eRJ) when compared with controls without RJ/eRJ 
supplementation (Figure 5.7 A and B). These results were statically significant, which 
indicated that RJ/eRJ improved functional proteostasis in aged C. elegans. 
Our previous results indicated that DAF-16 was required in RJ/eRJ mediated 
lifespan extension, stress resistance, and protection against Aβ toxicity. It is highly 
possible that DAF-16 might also be required in increasing the protein solubility under 
RJ/eRJ supplementation. In order to confirm this hypothesis, synchronized daf-16 
(mgDf50) mutant worms and daf-16 RNAi bacteria feeding CL-2006 worms were treated 
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with or without RJ/eRJ for 10 days. Then the aged worms were collected for total protein 
extraction. Sonication and centrifugation were utilized to remove the insoluble proteins, 
and the amount of soluble protein was measure by SDS-PAGE and Image-J software.  
Specifically, RJ/eRJ still increased the amount of soluble proteins by 5.44% (RJ) and 
2.20% (eRJ) when compared with the non-treated controls in daf-16 deletion mutant 
worms. Additionally, RJ/eRJ increased the amount of soluble proteins by 5.12% (RJ) and 
3.82% (eRJ) when compared with the non-supplemented controls in CL-2006 worms fed 
with daf-16 RNAi bacteria (Figure 5.8 A and B). However, the student t test showed that 
these increases were not statistically significant. To this end, these results indicated that 
RJ/eRJ cannot improve protein solubility of daf-16 deletion mutant worms and daf-16 
knocked down CL-2006 worms.  
Taken together, RJ/eRJ improved protein solubility in aged worms and thus 
delayed the development of AD. Noticeably, DAF-16 displayed a very important role in 
this process to maintain a healthy proteostasis. 
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Figure 5.7 RJ/eRJ improves proteostasis in aged C. elegans.  (A). RJ/eRJ 
treatment increased protein solubility in 10-day old N2 worms. (B). RJ/eRJ 
supplementation increased protein solubility in 10-day old CL-2006 worms. Soluble 
proteins on the SDS-PAGE gel were quantified by using Image-J software. Data were 
A 
B 
131 
 
expressed as mean intensity from three independent experiments. The standard errors of 
the mean (SEM) were shown. p value was calculated using Student’s t-test. “*” indicated 
p <0.05 when compared to controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
10-day old adult CL-2006  
fed with daf-16 RNAi bacteria  
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Figure 5.8 RJ/eRJ improves proteostasis in aged C. elegans dependent on DAF-
16.  (A). RJ/eRJ treatment increased protein solubility in 10-day old daf-16 (mgDf50) 
mutant worms. (B). RJ/eRJ supplementation increases protein solubility in 10-day old 
CL-2006 worms fed with daf-16 RNAi bacteria. Soluble proteins on the SDS-PAGE gel 
were quantified by using Image-J software. Data were expressed as mean intensity from 
three independent experiments. The standard errors of the mean (SEM) were shown. p 
value was calculated using Student’s t-test. “*” indicated p <0.05 when compared to 
controls. 
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5.2.5 RJ/eRJ supplementation significantly increases solubility of Aβ species in 
aged worms 
It is well known that healthy aging is often associated with functional proteostasis 
to reduce the proteotoxicity in cells. Given that RJ/eRJ could mitigate Aβ toxicity in AD 
worms, we wondered whether RJ/eRJ might promote the solubility of Aβ species in aged 
worms. To address this question, synchronized young adult CL-2006 worms were 
supplemented with or without RJ/eRJ for 10 days. Then the 10-day aged worms were 
collected for total proteins extraction. Sonication and centrifugation were utilized to 
divide proteins into soluble fraction and insoluble fraction. Afterwards, the amount of 
soluble Aβ species and insoluble Aβ species were measures by western blot and Image-J 
software. Our results showed that RJ/eRJ increased solubility of Aβ species in aged AD 
worms. Specifically, comparing with non-treated controls, RJ/eRJ supplementation 
increased the amount of soluble Aβ species 21.71% (RJ) and 19.31% (eRJ), whereas the 
amount of insoluble Aβ species was decreased by 27.63% (RJ) and 28.61% (eRJ), 
respectively (Figure 5.9 A and B). Considering that RJ/eRJ dramatically slowed down the 
progression of paralysis in AD worms, this result indicated that RJ/eRJ might promote 
the solubility of Aβ species in a toxicity reduction manner. 
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Figure 5.9 RJ/eRJ improves solubility of Aβ species in aged CL-2006 worms.  
(A). RJ/eRJ supplementation increased soluble Aβ species in 10-day old CL-2006 worms. 
(B). RJ/eRJ supplementation decreased insoluble Aβ species in 10-day old CL-2006 
worms. The amount of soluble and insoluble proteins was quantified by using western 
blot and Image-J software. DATA were expressed as mean intensity from three 
independent experiments. The standard errors of the mean (SEM) were shown. p value 
was calculated using Student’s t-test. “*” indicated p <0.05 when compared to controls. 
 
 
 
 
 
 
 
 
 
 
 
 
136 
 
5.3 Discussion 
In chapter three and four, our results showed that RJ/eRJ supplementation had 
beneficial effects of pro-longevity and stress resistance in C. elegans. A growing body of 
evidence suggests that some anti-aging nutraceuticals could delay the development of 
neurodegenerative diseases[123, 146, 195]. For example, cranberry protected C. elegans 
from thermal stress and slowed down the development of AD; Resveratrol, an antioxidant 
component from grape seed, not only had pro-longevity function but also delayed the 
development of Alzheimer’s diseases and Parkinson’s disease[147]. Therefore, it is 
interesting to further investigate whether RJ/eRJ also has the capacity to slow down the 
development of Alzheimer’s disease.  
CL-2006 mutant stain, an AD C. elegans model, which transgenically expresses 
human Aβ3-42 in the worms’ body muscle cells, has been considered as a well-established 
model to investigate the link between AD and Aβ pathology[192]. During the aging 
process, Aβ species were aggregated and accumulated inside and outside the muscle and 
neuron cells, which causes the worms’ body paralysis via deposition of cytotoxic plaques. 
To date, paralysis is a direct indicator to reflect Aβ toxicity in AD worms. 
In our study, our results showed that RJ/eRJ supplementation reduced the total 
amount of Aβ species and thereby delayed the progression of paralysis in AD worms. 
Additionally, RJ/eRJ supplemented CL-2006 worms’ lifespan. It is worth noticing that RJ 
treatment better protected AD worms from Aβ toxicity when compared with eRJ 
treatment. Our paralysis assay results showed that RJ/eRJ treatment increased the mean 
time of paralysis by 16.10% (RJ) and 10.92% (eRJ) when compared with the mean 
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paralysis time in non-supplemented controls in CL-2006 worms feeding with OP50 E. 
coli (figure 5.2 A and Table 7). Moreover, RJ/eRJ supplementation extended the mean 
paralysis time by 21.48% (RJ) and 15.61% (eRJ) when compared with the mean paralysis 
time in non-supplemented controls in CL-2006 worms feeding with RNAi control (L4440 
empty vector) bacteria. In addition to these two sets of data, another RNAi control 
(PAD12 empty vector) bacteria treatment also showed the same trend that RJ extended 
nearly 1 day longer of mean paralysis when compared with the mean time of paralysis in 
eRJ treatment. In agreement with these paralysis assay results, our dot blot assay showed 
that RJ treatment reduced 21.49% Aβ species, while eRJ treatment only reduces 14.51% 
Aβ species. 
As we mentioned in chapter three, the difference between the two types of RJ 
powders is that RJ contains more large proteins than eRJ powder. It is possible that these 
large proteins might promote immune response to eliminate toxic Aβ species. In 
agreement with these paralysis assay results, our dot blot assay showed that RT treatment 
reduced the Aβ species by 21.49%, while eRJ treatment only reduced the Aβ species by 
14.51%, comparing with the amount of Aβ species in non-supplemented controls. 
However, further experiments are needed to be done to better elucidate the different 
beneficial effects between RJ and eRJ powders. 
In our study, CL-2006 worms were treated with RJ/eRJ after L4/young adult stage 
rather than egg stage. The reason was that RJ/eRJ affected the hatching rate and 
development of CL-2006 worms. This negative effect was only observed in CL-2006 
strain rather than other types of worms in the previous study. Based on our observation, 
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when CL-2006 worms were treated with RJ/eRJ from the egg stage, their hatching rate 
and worms’ size were reduced when compared with that of non-treated CL-2006 worms. 
To note, these negative effects were even worse in RJ treatment than eRJ treatment. It is 
possible that RJ/eRJ might contain some proteins to reduce CL-2006 worms’ hatching 
rate and affect their development to a certain degree. Moreover, the large proteins in RJ 
powder might dramatically exacerbate these negative effects.  
Generally, although there were some differences between RJ/eRJ’s protein 
component and beneficial effects, both RJ and eRJ could slow down the progression of 
Aβ toxicity induced paralysis. Considering that CL-2006 worms’ Aβ species were human 
derived, it is highly possible that RJ/eRJ supplementation might have potential capacity 
to mitigate Aβ toxicity in humans. However, clinical research is needed to further 
confirm this hypothesis.  
As shown in this chapter, RJ/eRJ supplementation possessed the ability to 
alleviate Aβ toxicity in AD worms. However, the molecular mechanism underlying this 
beneficial effect is unknown. Moll and colleagues reported that reduction of Insulin 
Signaling (IIS) Pathway could prevent neurodegeneration in worms and mammals. They 
demonstrated that the reduction of IIS pathway could activate its three important 
transcriptional factors. DAF-16, HSF-1, and SKN-1, to inhibit age-mediated 
proteotoxicity and thereby maintain a healthy aging[144]. It is possible that IIS pathway 
and its three important transcriptional factors might also play a key role in RJ/eRJ 
mediated protection against Aβ toxicity. To address this concern, RNA interference 
(RNAi) was utilized to inhibit the gene expression of two important components (daf-2 
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and age-1) and three transcriptional factors (daf-16, skn-1, and hsf-1), respectively, to 
conduct genetic epistasis assays. Our findings indicated that IIS and DAF-16, rather than 
HSF-1 and SKN-1 were required in this RJ/eRJ mediated beneficial anti-AD effect 
(Figure 5.3 and 5.5). Moreover, quantitative PCR experiments were carried out to test 
whether DAF-16’s trans-activity is influenced by RJ/eRJ supplementation.  As expected, 
the increased level of sod-3 and mtl-1 confirmed that RJ/eRJ supplementation elevated 
the transactivity of DAF-16. Additionally, other DAF-16 target genes, Y71H2AR.2, hsp-
12.6, and hsp-16.2, were also up-regulated in RJ/eRJ treated CL-2006 worms (Figure 5.4). 
Taken together, the genetic analysis and quantitative PCR results indicated that RJ/eRJ 
alleviated Aβ toxicity via influencing IIS pathway to elevate the transactivity of DAF-16. 
SKN-1 and HSF-1 are also important factors to protect organisms from 
proteotoxicity by maintaining a healthy proteostasis. For example, HSF-1 regulates 
numerous heat shock proteins (HSPs) to facilitate the refolding of misfolded proteins in 
neurodegenerative diseases[37]. Similarly, SKN-1 also plays an important role in 
controlling protein quality and regulating detoxification of proteome[40, 196]. It is well 
known that a functional proteostasis could reduce the proteotoxicity and thereby alleviate 
the progression of paralysis. However, our genetic results showed that RJ/eRJ 
supplementation still dramatically extended the mean time of paralysis dramatically when 
compared with non-treated controls in hsf-1 RNAi bacterial treatment and skn-1 RNAi 
bacterial treatment (Figure 5.5) when compared the data among these two treatments and 
paired RNAi control (L4440 empty vector) bacteria, the increasing rates of mean 
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paralysis time were nearly the same (Table 9). This result further confirmed that SKN-1 
and HSF-1 were dispensable in RJ/eRJ mediated protection against Aβ toxicity. 
In addition to IIS pathway, the JNK pathway is also reported as an important 
regulator in neurodegenerative disorders. Specifically, Chen’s lab demonstrated that JNK 
pathway was significantly up-regulated in AD mammalian models[197]. Based on our 
knowledge, JNK-1, an essential regulator in the JNK pathway, could modulate DAF-16, 
HSF-1, and SKN-1 in parallel to IIS pathway. Intriguingly, our results showed that 
RJ/eRJ treatment extended the same rates of mean paralysis in CL-2006 worms feeding 
with jnk-1 RNAi bacteria and paired RNAi control (L4440 empty vector) bacteria (Figure 
5.5 and Table 9). These results indicated that JNK pathway was not required in RJ/eRJ 
mediated protection against Aβ toxicity.  
In chapter three and four, our research revealed that besides DAF-16, co-factors 
SIR-2.1, HCF-1, and 14-3-3 also play a very important role in RJ/eRJ mediated pro-
longevity and stress resistance. Based on these results, we questioned whether these three 
DAF-16 co-factors are involved in RJ/eRJ mediated anti-AD function. Our results 
showed that SIR-2.1, rather than HCF-1 and 14-3-3, were partially required in RJ/eRJ 
mediated protection against Aβ toxicity. Unlike DAF-16, SIR-2.1 was partially involved 
in RJ/eRJ mediated anti-AD effect, because our genetic data showed that RJ/eRJ still 
extended the mean time of paralysis by by 7.07% (RJ) and 7.03% (eRJ) in CL-2006 
worms feeding with sir-2.1 RNAi bacteria (Table 10), but this increasing rate was only 
half of the increasing rate in worms fed with CL-2006 RNAi control bacteria.  
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Numerous studies have revealed that SIRT1/SIR-2.1 plays a key role in 
prevention of neurodegenerative diseases. Araki reported that SIRT1 repressed axonal 
degeneration to decrease neuronal death rate in AD and Parkinson’s disease in murine 
model[198]. Besides neuronal protection, Chen lab discovered that overexpression of 
SIRT1 could inhibit NF-κB signaling via decreasing the acetylation of RelA/P65, which 
in turn protected mice against Aβ toxicity in AD development[199]. In agreement with 
their mammalian studies, our results showed that SIR-2.1 was partially involved in 
RJ/eRJ mediated protection against Aβ toxicity. Given that SIR-2.1 is an important DAF-
16 co-factor to fine-tunes DAF-16’s transactivity in RJ/eRJ mediated pro-longevity and 
stress resistance effects, it is conceivable that SIR-2.1 might modulate DAF-16’s 
transactivity to slow down the progression of CL-2006 worms’ paralysis under RJ/eRJ 
supplementation. Further experiment is needed to better understand the function of SIR-
2.1 in neurodegenerative diseases. Taken together, although three DAF-16 factors-SIR-
2.1, HCF-1, and 14-3-3-were involved in pro-longevity and stress resistance under 
RJ/eRJ supplementation, only SIR-2.1 was further required in RJ/eRJ mediated 
protection against Aβ toxicity in the AD worm model. 
Considering that RJ/eRJ supplementation mediated anti-AD effect acted through 
IIS pathway and DAF-16, we further questioned how IIS/DAF-16 functions in this 
process. Several studies demonstrated that the imbalance of proteostasis is often linked to 
neurodegenerative diseases. For instance, Ben-Zvi further demonstrated that an age-
related protein homeostasis disorders may lead to impaired protein solubility and 
increased cytotoxicity[190]. Reis-Rodrigues and colleagues further claimed that 
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accumulation of insoluble proteins with diverse biological functions may be shared as a 
general feature of normal aging and late onset neurodegenerative diseases[200]. The 
collective research of these age-related studies showed that better protein solubility 
directly reflects the heathier proteostasis and lower proteotoxicity. Interestingly, our 
results showed that RJ/eRJ significantly increased protein solubility in aged wild type 
worms and AD worms, which indicated that RJ/eRJ treated worms acquired the capacity 
to maintain a healthy proteostasis. Our previous results showed that DAF-16 was 
required in RJ/eRJ mediated protection against Aβ toxicity, which implied that RJ/eRJ 
might also require DAF-16 to retain a healthy proteostasis. In accordance with this 
hypothesis, our further solubility assay showed that the protein solubility of aged daf-16 
deletion mutant worms was barely influenced by RJ/eRJ supplementation. Taken together, 
our results indicated that RJ/eRJ improved the healthy proteostasis to mitigate Aβ 
toxicity in aged worms. This beneficial effect was dependent on DAF-16. 
It is worth noticing that RJ/eRJ supplementation remarkably increased the 
solubility of high molecular weight (HMW) proteins (protein size over 70 KD) by more 
than 2 fold when compared with the increasing rates of solubility for low molecular 
weight (LMW) proteins (protein size smaller than 70 KD) (Figure 5.10 A and B). 
However, in daf-16 (mgDf50) and daf-16 RNAi feeding AD worms, this difference of 
increasing ratios in HMW soluble proteins and LMW soluble proteins was abolished, 
indicating that DAF-16 played a very important role in maintaining the configuration of 
large soluble proteins (Figure 5.10 C and D).  As of yet, there is no conclusive evidence 
143 
 
proving the relationship between the well-maintained conformation of LMW and healthy 
aging, but the further research would confirm this relationship.  
To date, more and more research lab focus on investigating the link between Aβ 
conformation and its toxicity. Several clinical studies revealed that the amount of Aβ 
species detected in AD patients was not always higher than healthy people, which 
indicated that the amount of Aβ species is not a direct indicator to determine AD[201]. 
Furthermore, numerous studies have shown that not all of Aβ species are toxic to induce 
AD pathology, and the toxicity of Aβ species were dependent on their conformation[202]. 
Specifically, some scientists discovered that LMW Aβ/ Aβ oligomers which prone to 
seed Aβ aggregation could accelerate the development of neurodegenerative diseases and 
proteinopathy[203]. Although the detailed molecular mechanism of proteotoxicity 
underlying neurodegenerative diseases is still unclear, numerous studies demonstrated 
that IIS pathway and its three critical transcriptional factors play an important role to 
regulate protein aggregation and proteotoxicity. In order to decipher the molecular 
mechanism of Aβ induced cytotoxicity, Cohen research lab reported that DAF-16 can 
promote protein aggregation to protect cells from the accumulation of soluble and toxic 
protein species[204]. 
 In our research, the solubility results implied that DAF-16 was regulated by 
RJ/eRJ supplementation to increase more than 2 times of soluble HMW proteins than 
LMW proteins in aged worms. There are two possible reasons to explain this 
phenomenon. First, in agreement with Cohen’s discovery, DAF-16 could promote soluble 
LMW proteins aggregation to form more soluble HMW proteins in aging process. 
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Another possibility is that DAF-16 protected HMW proteins from degradation by 
retaining their soluble status conformation and stability. Based on our results, it is hard to 
tell whether DAF-16 functions to promote protein aggregation or prevent the degradation 
of HMW proteins. Therefore, further research was needed to be carried out to investigate 
DAF-16’s function in proteostasis. Taken together, our findings suggested that RJ/eRJ 
supplementation improved the healthy proteostasis by maintaining the functional protein 
conformation in aged worms.  
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Figure 5.10 RJ/eRJ supplementation remarkably increases the solubility of 
high molecular weight (HMW) proteins (protein size over 70 KD) more than 
low molecular weight (LMW) proteins in a DAF-16 dependent manner.  (A). 
RJ/eRJ treatment increased more HMW protein solubility than LMW protein solubility in 
10-day old N2 worms. (B). RJ/eRJ treatment increased more HMW protein solubility 
than LMW protein solubility in 10-day old CL-2006 worms. (C). RJ/eRJ treatment 
increased same ratio of HMW protein solubility and LMW protein solubility in 10-day 
old daf-16 (mgDf50) worms. (D). RJ/eRJ treatment increases same ratio of HMW protein 
solubility and LMW protein solubility in 10-day old CL-2006 worms feeding with daf-16 
RNAi bateria. Soluble proteins on the SDS-PAGE gel are quantified by using Image-J 
software. Data were expressed as mean intensity from three independent experiments. 
The standard errors of the mean (SEM) were shown. p value was calculated using 
Student’s t-test. “*” indicated p <0.05 when compared to controls. 
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It is well known that a healthy proteostasis indicates a balance of protein synthesis, 
folding, aggregation, and degradation. However, imbalance among these processes 
engenders deposition and aggregation of aberrant proteins, causing toxicity and damge to 
induce age-related disorders. In order to fight against this negative impact, cells are 
equipped with protective machinery to maintain a protein homeostasis in normal 
condition. The misfolded and unfolded proteins are usually refolded by HSPs or targeted 
by ubiquitin for proteasomal or lysosomal degradation[205]. However, this mechanism is 
overwhelmed in aging cells or under persisting harsh stresses conditions. As a result, the 
misfolded and unfolded proteins are aggregated and accumulated inside and outside the 
cells instead of being refolded or destroyed, and thus induces the neurodegenerative 
disorders. It is well known that HSPs function as a master regulator to maintain this 
important machinery in all conditions[187]. Several studies demonstrated that even 
overexpression of one HSP could dramatically delay the neurodegenerative diseases, 
which underscored HSPs’ critical function in retaining the healthy proteostasis. 
 In agreement with this view, RJ/eRJ supplementation also positively regulated 
the levels of several protein turnover genes in AD worms, such as mtl-1, hsp-12.6, hsp-
16.2, and Y71H2AR.2. mtl-1, an important downstream genes of DAF-16, plays an 
important role in metal detoxification and maintaining the protein homeostasis in stress 
conditions[206]. HSP-12.6 and HSP-16.2 are two essential heat shock proteins, which 
function as ubiquitous molecular chaperones to prevent the aggregation of misfolded and 
unfolded proteins in response to proteotoxic stressors[196, 207]. Additionally, Link’s lab 
discovered that overexpression of HSP-16.2 could suppress the Aβ toxicity in AD worms, 
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which might be selected as a target to design anti-AD drugs. The last gene dramatically 
influenced by RJ/eRJ treatment was Y71H2AR.2, which encodes a papain family cysteine 
protease to modulate proteolysis[208]. The up-regulated of this gene might indicate a 
well-maintained detoxification function to destruct the aberrant proteins. Besides protein 
folding and degradation, we also investigate whether RJ/eRJ supplementation could 
affect CL-2006 worms’ protein synthesis. Intriguingly, ZK218.8 and T05G5.10, which 
encode translation initiation factor 2C and 5A respectively, were not affected by RJ/eRJ 
supplementation in our quantitative PCR experiment[209]. Collectively, the elevated 
expression level of these DAF-16 targeted protein turnover genes indicated that RJ/eRJ 
improve the healthy proteostatic status by strengthening the function of protein folding 
and degradation in AD worms.  
Besides these genes, several protein turnover related genes’ level were also 
measured in our quantitative PCR experiment. sip-1 (stress induced protein 1) and hsp70 
are also reported to control protein quality, guide protein folding, and maintain proteins’ 
biological function[118, 210]. aip-1 (arsenite inducible protein) and F10D7.5 are 
important regulator to induce the degradation of toxic proteins under stress or disease 
conditions[209, 211]. To note, it is reported that aip-1 played an important role to 
regulate 26S proteasome in response to protein aggregation in AD. In contrast, no study 
demonstrated F10D7.5’s function in AD related research, but this gene encodes one of 
the E3 ubiquitin ligases in C. elegans, which could bind the target protein and E2 enzyme 
together to signal ubiquitin targeted protein degradation or modulate its function. 
Unfortunately, these genes were not affected by RJ/eRJ supplementation in AD worms. It 
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is well known that AIP-1, SIP-1, and HSP-70 were mainly regulated by HSF-1, and HSF-
1 was not required in RJ/eRJ mediated protection against Aβ toxicity. Thus this result 
further confirmed our genetic data and supported our proposed genetic model. 
Additionally, this result indicated that DAF-16’s activity is fine-tuned by co-factors and 
pathways. Further experiments are needed to best understand the precise post-
translational modification of DAF-16 under RJ/eRJ supplementation, which will provide 
novel ideas to develop effective anti-AD drugs. 
Given that RJ/eRJ supplementation could promote the functional proteostasis to 
attenuate proteotoxicity in aging cells, next we tested whether RJ/eRJ mediated Aβ 
detoxification acted through affecting the solubility of Aβ species. Our results showed 
that RJ/eRJ supplemented worms’ soluble Aβ species were significantly higher than non-
treated CL-2006 worms, while the insoluble Aβ species in RJ/eRJ treated worms were 
dramatically lower when compared with non-treated controls (Figure 5.9 A and B). In 
consideration of RJ/eRJ possessed the ability to alleviate Aβ toxicity in AD worms, our 
finding suggested that RJ/eRJ mediated Aβ species detoxification might act through 
changing the conformation of Aβ proteins to alleviate its toxicity in AD worms. 
Tyedmers and colleagues reported that the forming aggregates’ structure varied from 
most disordered aggregates to prefibrillar species and highly ordered amyloid fibrils in 
AD patients’ cells. Comparing with highly ordered aggregates, the unstructured and 
disordered aggregates are dramatically inclined to be degraded and thereby be considered 
as less toxic aggregates. Noticeably, chaperones play an important role in this aggregates 
formation process[131, 212]. Given that RJ/eRJ changed the solubility of Aβ species in 
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aged worms and up-regulated the levels of several chaperone proteins, it is possible that 
RJ/eRJ could promote the formation of disordered Aβ aggregates instead of highly 
ordered insoluble Aβ aggregates and hence improves the detoxification of Aβ species in 
AD worms. 
Further experiment is needed to be carried out to best understand how Aβ 
conformation is changed and detoxified by DAF-16. Numerous studies revealed that the 
Aβ3(PE)-42 was one type of toxic Aβ species, which formed more than 50% of Aβ plaques 
in cells and seeded Aβ aggregation to accelerate the development of AD. Accordingly, 
glutaminyl cyclase (QC) has been proposed to catalyze Aβ3-42 to Aβ3(PE)-42 in clinical 
study to exacerbate neuronal cytotoxicity. It is possible that RJ/eRJ might possess 
capacity to affect Aβ species conformation by influencing QC[213]. Currently, there is no 
publication talking about the link between Aβ conformation and QC in C. elegans model, 
and further research will investigate this relationship.  
Overall, our finding not only demonstrated that the molecular mechanisms of 
RJ/eRJ mediated alleviation of Aβ toxicity in C. elegans but also underscored RJ/eRJ’s 
potential function to lead a healthy aging. In considering that IIS/DAF-16 is highly 
conserved in species ranging from C. elegans to human and RJ/eRJ mediated healthy 
proteostasis is dependent on the regulation of IIS/DAF-16, it is highly possible that 
RJ/eRJ might also be beneficial for human consumption to prevent or slow down the 
onset neurodegenerative diseases. 
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CHAPTER SIX CHAPTER SIX: FUTURE DIRECTION 
In previous chapters, our findings indicated that Royal Jelly (RJ/eRJ) 
supplementation extended C. elegans lifespan, increased their stress tolerance, and 
protected against Aβ toxicity in AD worms. Intriguingly, this anti-aging effect acted 
through increasing the transcriptional activity of DAF-16 and, in turn, improving the 
healthy proteostasis in C. elegans. To this end, our studies not only revealed the 
molecular mechanism underlying RJ/eRJ mediated beneficial effects but also 
underscored the essential function of Insulin Signaling Pathway (IIS) and DAF-16 under 
aging and disease conditions.  
It is well known that DAF-16/FOXO, a highly conserved forkhead transcriptional 
factor from C. elegans to mammals, is tightly regulated by post-translational 
modifications (PTMs) and protein-protein interaction with its co-factors[214]. Noticeably, 
DAF-16/FOXO plays a very important role in cell proliferation, energy metabolism, and 
stress response. Additionally, DAF-16/FOXO supports the survival of organisms under 
low glucose and fasting conditions, and protects cells from stress-induced cellular 
damages. However, the dysregulation of DAF-16/FOXO results in age-related disorders, 
such as cancer, diabetes and neurodegenerative diseases[35]. Based on DAF-16/FOXO’s 
important anti-aging functions, it is worth studying how the regulatory specificity of 
DAF-16/FOXO is determined in cells under normal and aging conditions. 
Numerous studies demonstrated that FOXO transcriptional factors are regulated 
by certain external factors, including nutrients, environmental stressors, and cytokines. 
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These external stimuli could induce the post translational modifications of FOXO to alter 
its structural and functional properties, which in turn regulate the subcellular location and 
transactivity of FOXOs. To date, phosphorylation, acetylation and ubiquitylation are 
best-studied PTMs of FOXOs.  
It has been proposed that FOXO phosphorylation is often induced by signaling 
pathways and cellular stresses. For instance, under the activation of IIS pathway, 
AKT/PKB phosphorylates FOXO and, in turn, sequesters FOXO in the cytosol rather 
than assists their nucleus translocation. In contrast, under oxidative stress, the c-Jun N-
terminal kinase (JNK) pathway phosphorylates FOXO and thereby increases its 
transactivity to protect cells from oxidative damage. Taken together, the different sites of 
FOXO phosphorylation result in opposite functions in cells, either activation or 
inactivation of FOXO, which highlights the link between precise PTMs and specific 
functions[45].  
In addition to phosphorylation, another frequently observed PTM of FOXO is 
acetylation. Under the oxidative stress, FOXO can bind to several histone 
acetyltransferanse (HATs) , which might reduce the DNA binding capacity of FOXO and 
thereby decrease its transactivity. However, this negative effect can result in reduced 
HDACs (histone deacetylases). It is reported that in mammalian models, FOXOs are 
acetylated by HATs, such as P300/CBP and CBP-associated factor (P/CAF) and 
deacetylated by SIRT1[215]. 
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In addition to phosphorylation and acetylation, ubiquitylation also modulates 
FOXO’s activity. Several studies have described that polyubiquitylation leads to the 
proteasomal degradation of FOXOs, whereas monoubiquitylation strongly increases the 
transcriptional activity of FOXOs. In addition to these three PTMs, methylation and 
glycosylation also regulate FOXO’s activity. In our research, RJ/eRJ significantly up-
regulated the activity of DAF-16, but further experiments are needed to be done to 
investigate which types of DAF-16’s PTMs are triggered in RJ/eRJ supplementation 
under normal and disease conditions[216]. 
Furthermore, as well as PTMs, several co-factors (binding partners) also modulate 
FOXO’s activity and function. For instance, co-factor 14-3-3 could bind and sequester 
DAF-16 in the cytosol under the activation of IIS pathway, which represses the DAF-16’s 
nucleus translocation. However, under heat shock stress, 14-3-3 functions as a bridging 
protein to promote the physiological interaction of DAF-16 and SIR-2.1, which in turn 
increases the transactivity of DAF-16 in the C. elegans model. Another important DAF-
16 co-factor is HCF-1, which also physiologically interacts with DAF-16 and represses 
its activity. Specifically, in our research we found that SIR-2.1, 14-3-3 and HCF-1 were 
required to modulate DAF-16’s activity under RJ/eRJ supplementation. Moreover, 
besides of these three co-factors, other DAF-16 binding partners might be also involved 
in RJ/eRJ mediated anti-aging effect, such as BAR-1, SMK-1 and RLE-1[159]. Further 
experiments are needed to be carried out to better understand the detailed molecular 
mechanism underlying this intricate protein-protein interaction[48, 49, 65].  
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Overall, RJ/eRJ supplementation provides us a good nutrigenetic model to further 
investigate the precise mechanism of how DAF-16/FOXO is regulated under aging and 
disease conditions. 
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Figure 6.1 Summary of post-translational modifications on the various FoxO 
isoforms.  (Horst et al., 2007) 
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In order to approach our goal, several experiments are needed to conduct in the 
future. Firstly, we wondered what PTMs of DAF-16 are triggered under RJ/eRJ 
supplementation. The wildtype N2 and AD worms will be supplemented with RJ/eRJ for 
several days, and then the purified DAF-16 proteins will be analyzed by MS-Spec 
methods to analyze their PTM pattern. After comparing the differences between RJ/eRJ 
treated worms and non-treated controls, we will determine the types of PTMs on DAF-16 
triggered by RJ/eRJ supplementation. Noticeably, this unique pattern on DAF-16 could 
be utilized as an indicator to screen efficient anti-AD drugs. As well as we know the 
RJ/eRJ mediated specific PTMs of DAF-16, we will further investigate the protein-
protein interaction between DAF-16 and its binding partners, which will help us to better 
understand how the regulatory specificity of DAF-16 is determined in healthy and aging 
cells. 
In conclusion, our findings revealed the molecular mechanism of RJ/eRJ’s anti-
aging effect, and underscored the link between an improving proteostasis and a healthy 
aging. Moreover, we highlight that IIS/DAF-16 plays a key role in pro-longevity, stress 
resistance and age-related disease prevention. 
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